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ABSTRACT

Neurons are among the most highly polarized cells in the human body. This
polarization allows the neuron to participate in the transfer of chemical and electrical
signals which are crucial to the survival of the organism. As part of polarization, each
neuron develops a dendritic arbor and an axon. To ensure the survival of the cell,
materials synthesized in the cell body must be trafficked through the axon for delivery
throughout ultimately ending at the synaptic termini. The bulk of this cargo transport is
microtubule-based fast axonal transport which is molecular motor mediated and tightly
regulated though many pathways. Motor based transport is established early in
development and maintained for the life of the cell. The kinesin motor protein family
plays an integral role in fast axonal transport and the regulation of these motors is
essential to proper cargo delivery. Regulation occurs through auto-inhibition, motor
interactions with microtubule associated proteins (MAPs) and complex signaling
pathways which control the post-translational modification of MAPs, the microtubule
track and the motors.
The disruption of cargo transport is linked to neurodegeneration and disease state
development. Of particular interest in this process is the MAP Tau which has been
implicated in a number of neurodegenerative diseases including Alzheimer’s Disease.
Tau is expressed at all stages of neural development and has been shown to participate in
signaling cascades, modulate microtubule dynamics and preferentially inhibit kinesin-1
motility. Though Tau is involved in these processes, the non-disease state regulation of
this MAP and it’s inhibition of kinesin-1 is not well understood. Tau has been shown to
bind the microtubule surface in a static-diffusive state equilibrium which differs with
isoform and lattice. Previous work demonstrates that the static state is more inhibitory to
kinesin-1 than the diffusive state. These different binding behaviors with their different
effects on kinesin-1 motility, suggest that cellular regulation of Tau’s static-diffusive
binding equilibrium may control inhibition of kinesin-1 and that structural changes may
underlie Tau binding to the microtubule surface. Cellular regulation of Tau’s structure
and therefore its behavior on the microtubule surface points to a means by which Tau is
regulated in the non-disease state. Additionally, this would highlight how early changes
lead to disease state development.
Using a combination of molecular biology, biochemical techniques and imaging
strategies including Total Internal Reflection Fluorescence, single molecule Fluorescence
Resonance Energy Transfer (smFRET) and Alternating Laser Excitation, we show that
Tau’s static-diffusive state equilibrium is regulated by non-disease state phosphorylation
at tyrosine 18. Phospho-mimetics are shifted towards diffusive binding and have
decreased affinity for the microtubule surface which in turn reduces inhibition of kinesin1 motility. These results further demonstrate that Tau undergoes long range structural
change while bound to the microtubule surface. We performed smFRET assays and
found that Tau binds the microtubule surface in distinct conformations which underlie
static and diffusive binding. This work ties the regulation of Tau’s structure and binding
behavior to its function and paves the way for our understanding of how cellular
regulation acts on multiple levels to fine tune axonal transport.
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CHAPTER 1: LITERATURE REVIEW
1.1 Neuronal Development and Degeneration
1.1.1 The Neuron Theory
The Nobel Prize in Physiology and Medicine was awarded to Camillo Golgi and
Santiago Ramón y Cajal in 1906 (Golgi, 1906; Ramón y Cajal, 1906). In his acceptance
speech, Ramón y Cajal described data generated using staining methods developed by
Golgi in support of the idea that discrete cellular units called neurons compose the
nervous system (Ramón y Cajal, 1906).
During the early years of the development of neurology, work by Ramón y Cajal,
Van Gehuchten and others revealed that neurons are electrically excitable cells that
develop a uniquely polarized structure consisting of a cell body from which multiple
dendrites branch and a single axon extends (Figure 1.1) (Ramón y Cajal, 1906; Pasik et
al., 1999; Ling et al., 2012; Levitan and Kaczmarek, 2015). The interaction of a dendrite
with an axon terminal creates a cell-cell junction known as the synapse (Levitan and
Kaczmarek, 2015). At the synapse, electrical impulses propagated down the axon are
either directly transmitted to the other neuron or converted to chemical signals which
bridge the gap between the axon and the dendrite (Levitan and Kaczmarek, 2015).
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Figure 1.1: Pyramidal neuron
A) The axon of the pyramidal neuron (horizontal arrow) descends to the white matter,
but also sends branches (vertical arrows) horizontally. Double arrows indicate the
region shown in the inset, rotated 90° clockwise, that illustrates spiny appendages
(arrowheads) distributed along a segment of a labeled dendrite. B) Camera lucida
drawing of the labeled neuron shown in A to illustrate the entire dendritic arbor of the
neuron. Scale bar: 75 µm in A, 50 µm in B, and 10 µm for the inset in A. Figure and
legend adapted from Ling et al., (2012) in accordance with the Creative Commons
Attribution license.
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1.1.2 Neural Development
The nervous system begins to develop within the first gestational month (Stiles
and Jernigan, 2010). In humans on embryonic day 13 (E13), complex signaling pathways
facilitate gastrulation – the development of three layers of stem cells including the
neuralectodermal (neural progenitor) cells (Stiles and Jernigan, 2010). These cells will
eventually give rise to all the components of the brain and central nervous system. Neural
progenitor cells undergo successive rounds of symmetric cell division between E25 and
E42 to provide a pool from which neurons can develop (Stiles and Jernigan, 2010). After
E42 symmetric cell division gives way to asymmetric division which produces one
progenitor cell and one neuron (Wodarz and Huttner, 2003).

1.1.3 Axonal Development
Each neuron must develop a dendritic arbor and an axon. Axonal development is
dependent on growth cone formation (Kalil and Dent, 2014). The growth cone is a mobile
leading edge which upon development, grows outwards from the cell in response to
guidance cues such as nerve growth factor (NGF), brain derived neurotrophic factor
(BDNF), netrins, ephrins and semaphorins (Gibney and Zheng, 2003; Kalil and Dent,
2014). Netrins ephrins and semaphorins can act as both attractive and repulsive factors
depending on the receptor present (Moore et al., 2007; Kalil and Dent, 2014). The
combination of attractive and repulsive cues shapes the trajectory of the growth cone,
regulates axon branching and prevents axon crossing (Kalil and Dent, 2014). The
mobility of the growth cone is due to the organization of a complex cytoskeletal structure
3

consisting of both actin and microtubule based components (Kalil and Dent, 2014). The
growth cone can be divided into a peripheral region of dynamic actin cytoskeleton which
produces lamellipodia- and filopodia-like structures and a central region with a dense
microtubule cytoskeleton (Kalil and Dent, 2014). Both actin and microtubules are
polymers which grow and shrink dynamically (Kalil and Dent, 2014). Actin is a globular
protein that forms filaments through the binding and hydrolysis of ATP while
microtubules are comprised of globular tubulin heterodimers that form tubules through
the binding and hydrolysis of GTP (Korn et al., 1987; Desai and Mitchison, 1997; Kalil
and Dent, 2014).
The microtubules in the central region are essential for stabilizing the axon as it
develops (Kalil and Dent, 2014). These microtubules are organized with their plus ends
oriented away from the neuronal cell body (Kalil and Dent, 2014). This orientation
allows the microtubule bundles to act as highways for the retrograde/anterograde
transport of cargo critical to the development and maintenance of the axon (Kalil and
Dent, 2014). Cargo transport is largely a molecular motor based process which is tightly
regulated by the cell (Stenoien and Brady, 1999) .
Neurons establish polarity once they exit the cell cycle (Barnes and Polleux,
2009). In some cases, polarity is the result of the apico-basal arrangement of the cell as is
the case for mouse retinal ganglion cells (Figure 1.2) (Barnes and Polleux, 2009). Upon
cell cycle exit, the cell body migrates from the apical to the basal membrane forming a
trailing and leading process (Polleux and Snider, 2010). Dendrites develop from the
apical process while the axon is formed from the basal process (Figure 1.2) (Barnes and
Polleux, 2009). Not all neuronal cell types immediately form a single trailing and leading
4

edge. Mouse pyramidal neurons for example, through the action of cyclin dependent
kinase 5 (Cdk5), produce many processes or neurites before a trailing (axon) and leading
(dendrites) process form (Figure 1.3) (Barnes and Polleux, 2009; Liu et al., 2016).
Polarization is therefore the result of cross-talk between extracellular cues, intracellular
signaling and extensive cytoskeletal rearrangements.
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Figure 1.2: In vivo polarization of retinal ganglion cells in zebrafish (Danio rerio)
and mouse (Mus musculus).
Neuroepithelial progenitors characterized by an apical and a basal attachment undergo
asymmetrical cell division at the apical surface (1–3). Upon cell cycle exit, the nucleus
undergoes basal translocation (4) and specifically loses its apical attachment while its
basal process starts growing along the basal membrane (5). The axon (purple) develops
from the basal process and the dendrite from the apical process (6; green). Figure and
legend adapted from Barnes and Polleux, (2009). Republished with permission of Annual
Review of Neuroscience from Barnes, A.P., and Polleux F. (2009). Establishment of
axon-dendrite polarity in developing neurons. 32, 347-381 permission conveyed through
Copyright Clearance Center, Inc.
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Figure 1.3: Polarization of radially migrating pyramidal neurons in the mammalian
neocortex.
Neurons are generated between E11 and E17 by radial glial progenitors in the ventricular
zone (VZ) of the mouse neocortex. These cells have a long basal process attached to the
basal membrane and a short apical process on the ventricle side (1). Upon cell cycle exit
through asymmetric cell division (2), the postmitotic neuron (blue) goes through a
multipolar transition where multiple neurites emerge rapidly from the cell body (3) before
two major processes form (4) and become the leading process (LP) and trailing process
(TP). The cell body continues to translocate toward its final destination while the axon
rapidly elongates (6). The leading process gives rise to the apical dendrite (green in 7),
which initiates local branching in the marginal zone (MZ) while over the first postnatal
week (until radial migration ends) the cell body will translocate ventrally (8). Figure and
legend adapted from Barnes and Polleux, (2009). Republished with permission of Annual
Review of Neuroscience from Barnes, A.P., and Polleux F. (2009). Establishment of
axon-dendrite polarity in developing neurons. 32, 347-381 permission conveyed through
Copyright Clearance Center, Inc.
7

In mammals, axons have been shown to develop in response to external growth
cues such as BDNF (Polleux and Snider, 2010). In in vitro experiments with hippocampal
neurons plated on stripes of adhesion molecules, the neurite which encounters BDNF first
becomes the axon (Shelly et al., 2007). BDNF acts through Ras mediated activation of
cyclic adenosine monophosphate (cAMP) dependent protein kinase (PKA) (Figure 1.4)
(Shelly et al., 2007). Repulsive cues such as semaphorin 3A play a role in directing axon
development in cortical neurons where axons develop ventrally (Polleux et al., 1998;
Chen et al., 2008). In Caenorhabditis elegans, axonal development is regulated by netrin
and its receptors deleted in colorectal cancer (DCC) and Uncoordinated 5 (unc-5) (Adler
et al., 2006). Soluble netrin gradients act as attractive cues in the presence of DCC (Adler
et al., 2006). With repulsive cues directing growth away from an undesirable area and
gradients of attractive cues promoting growth in another direction, the growth cone can
be steered to its final destination. Downstream effectors of netrin/DCC signaling include
phosphatidylinositol 3 kinase (PI3K), phosphatase and tensin homolog deleted on
chromosome
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(PTEN)

and

the

Ena/VASP

(enabled/Vasodilator-

stimulated phosphoprotein) homolog unc-34 which binds actin promoting filament
formation and therefore filopodia formation (Fleming et al., 2010; Polleux and Snider,
2010).
In response to external cues (such as BDNF or netrin), the serine/threonine
kinase, liver kinase B1 (LKB1; in C. elegans Par-3) is translocated from the nucleus upon
dimerization with sterile20-related kinase adaptor (STRAD) α/β (Dorfman and Macara,
2008) (Figure 1.4). In the cytoplasm, LKB1/STRAD is activated by PKA
8

phosphorylation (Collins et al., 2000). LKB1/STRAD in turn propagates this signal by
phosphorylating and activating the microtubule affinity regulating kinases (MARK) 1-4
which regulate microtubule dynamics by phosphorylating microtubule associated proteins
(Figure 1.4) (Polleux and Snider, 2010).

9

Figure 1.4: Signaling pathways governing axonal development.
External signaling cues such as netrins and BNDF, once bound to their receptors, activate
signaling pathways that ultimately converge on the cytoskeleton. Gradients of these
signaling cues direct axonal growth during development. Figure and legend created based
on Barnes and Polleux, (2009) and Polleux and Snider, (2010).
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Ras activation also leads to PI3K activity (Polleux and Snider, 2010; Zhong,
2016). PI3K has been shown to accumulate in the neurite destined to become the axon
(Barnes and Polleux, 2009). Constitutively active PI3K overexpression leads to the
development of multiple axonal processes while inhibition prevents axon formation
(Barnes and Polleux, 2009). PI3K activity is antagonized by PTEN (Barnes and Polleux,
2009). PTEN dephosphorylation of phosphatidylinositol triphosphate (PIP3), the product
of PI3K activation, limits PI3K signaling (Barnes and Polleux, 2009). Spatial regulation
of PI3K signaling by PTEN allows for single axon development (Barnes and Polleux,
2009). Overexpression of PTEN leads to the loss of axonal development while PTEN
knockdown allows multiple axons to develop (Barnes and Polleux, 2009).
PI3K downstream effectors include protein kinase B (AKT) which is recruited
to the membrane via PIP3 binding to its plextrin homology domain (Zhong, 2016). Once
at the membrane, AKT is phosphorylated and activated by other membrane targeted
kinases (Barnes and Polleux, 2009). Active AKT has been shown to localize to polarized
growth cones and constitutively active AKT gives rise to multi-axon neurons (Barnes and
Polleux, 2009). This mimics the effect of PI3K overexpression and places AKT in the
PI3K pathway governing polarization.
Given the dynamicity of the growth cone, it is not surprising that the signaling
cascades dictating axonal development converge on the cytoskeleton. In some instances,
the action of the cytoskeleton controls signaling forming a type of feedback loop. PI3K
for example, interacts with Shootin1 (Toriyama et al., 2006) and Singar 1/2 (Mori et al.,
2007). Of these two proteins, Shootin1 overexpression is sufficient to cause multi-axon
11

development (Barnes and Polleux, 2009). Interestingly, Shootin1 is transported to the
growth cone in a myosin dependent manner where is co-localizes with active PI3K
(Barnes and Polleux, 2009). Additionally, evidence suggests there are two pools of PIP3
at the growth cone, one produced by locally active PI3K and another transported pool
(Barnes and Polleux, 2009). The transportation of PIP3 vesicles to the forming axon is
dependent on guanylate kinase associated kinesin (GAKIN) (Barnes and Polleux, 2009).
GAKIN mediated transport of extra PIP3 may help maintain axon integrity through
maintenance of a high PIP3 concentration.
At the heart of polarity regulation lies glycogen synthase kinase 3 β (GSK3β).
GSK3β is constitutively active in its unphosphorylated form (Barnes and Polleux, 2009;
Polleux and Snider, 2010). GSK3β sits at the crossroads between signal cascades and
direct regulation of cytoskeletal elements. GSK3β is phosphorylated and deactivated by
AKT in the forming axon (Barnes and Polleux, 2009). Global inhibition of GSK3β
activity leads to multi-axon formation indicating that GSK3β activation must be
maintained in neurites destined to become dendrites while GSK3β must be inhibited by
AKT during axonal development (Barnes and Polleux, 2009).
The cytoskeleton then must support the transport of factors needed for axonal
development while rapid rearrangement occurs. This rearrangement occurs through the
action of multiple regulating proteins in addition to Ena/VASP such as collapsing
response mediator protein-2 (CRMP-2) (Barnes and Polleux, 2009). CRMP-2 is regulated
by GSK3β and binds directly to tubulin and the WASP-family verprolin homologous
(WAVE) protein complex to regulate both microtubule and actin dynamics (Barnes and
Polleux, 2009). Adenomatous polyposis coli another microtubule binding protein
12

regulated by GSK3β, is enriched in the forming axon at early time points (Barnes and
Polleux, 2009). GSK3β has also been shown to alter the phosphorylation state and
behavior of the microtubule associated proteins (MAPs) Tau and MAP1b (Barnes and
Polleux, 2009).

1.1.4 Neurodegeneration
The pathways that govern neural development and maintain cell function are
susceptible to myriad insults which eventually lead to disease state development. These
insults include environmental factors, traumatic injury, inherited and spontaneous
mutations, and disrupted/misregulated signaling (Brady and Morfini, 2017; Prior et al.,
2017; Wilson et al., 2017). Whether the insult is intra- or extracellular, the end result is
synapse loss and the eventual death of the neuron (Liu et al., 2011; Brady and Morfini,
2017; Prior et al., 2017).
One of the hallmarks of disease state development and neurodegeneration is the
disruption of cargo transport through the axon (Brady and Morfini, 2017; Prior et al.,
2017). The molecular motor mediated movement of cargo is established during
development and is maintained throughout the life of the cell (Brady and Morfini, 2017).
In the disease state aberrant signaling by misregulated kinases leads to inhibition of
motors and regulatory elements (Kanaan et al., 2013; Martin et al., 2013b).
Though many kinases contribute to disease state development (Martin et al.,
2013b; Brady and Morfini, 2017), for the sake of brevity only the action of GSK3β and
Cdk5 will be covered. GSK3β activity is regulated through inhibitory phosphorylation at
serine 9 (Kirouac et al., 2017). The tight control of this site allows for normal axonal
13

development and neuronal signaling (Llorens-Martin et al., 2014; Kirouac et al., 2017).
Disruption of signaling pathways (such as AKT activity) that inhibit GSK3β are common
to the development of neurodegenerative disease (Llorens-Martin et al., 2014).
In the development of Alzheimer’s Disease (AD), aberrant signaling through
amyloid precursor protein (APP) has been shown to upregulate GSK3β activity (Kirouac
et al., 2017). Disease state processing of APP by β- and γ-secretase generates the
extracellular fragment amyloid β (Aβ) and the APP intracellular fragment (AICD)
(Kirouac et al., 2017). AICD has been shown to bind and upregulate GSK3β which in
turn phosphorylates APP at threonine 688 increasing disease state cleavage (Kirouac et
al., 2017). This creates a positive feedback loop which keeps GSK3β active in the disease
state. As part of its non-disease state roles, GSK3β regulates cytoskeletal elements
(Barnes and Polleux, 2009; Polleux and Snider, 2010). Increased GSK3β activity leads to
increased phosphorylation and misregulation of these elements including molecular
motors such as kinesin-1 and MAPs such as Tau (Llorens-Martin et al., 2014; Brady and
Morfini, 2017). GSK3β is also upregulated independently of AICD in diseases such as
Progressive Supranuclear Palsy, Pick’s Disease and other forms of dementia (Ferrer et
al., 2002; Ferrer et al., 2003).
Unlike other members of the cyclin dependent kinase family, Cdk5 is not
regulated by cyclin expression but is active in post-mitotic neurons because of its
activators p35/p39 (Liu et al., 2016). These membrane bound activators are prone to
ubiquitination and degradation leading to short bursts of Cdk5 activity (Liu et al., 2016).
While active, Cdk5 has been shown to regulate the activity of other kinases including
GSK3β (Liu et al., 2016). In addition to controlling neurite formation, Cdk5 plays a role
14

in synaptic formation, myelination and maintenance of mitochondrial function (Liu et al.,
2016). In the disease state, prolonged calcium influx leads to calpain mediated cleavage
of p35 and p39 into their more stable forms p25 and p29 (Lee et al., 2000; Kurbatskaya et
al., 2016; Liu et al., 2016). The Cdk5/p25 interaction leads to the upregulation of Cdk5
activity and disease state phosphorylation of APP at threonine 688 (Liu et al., 2016).
Cdk5/p25 has also been shown to directly affect the cytoskeleton through
phosphorylation of the WAVE complex, CRMP-2 and MAPs such as Tau (Liu et al.,
2016). In addition to its association with Cdk5, p25 has been shown to bind and
upregulate GSK3β activity (Chow et al., 2014).
The disease state misregulation of signaling as demonstrated by GSK3β and
Cdk5, does not occur without extracellular cues or other perturbation. For example,
neurodegenerative diseases such as Alzheimer’s Disease share disease state conditions
with Diabetes including insulin resistance as the result of chronic metabolic stress and
inflammation (Liu et al., 2011). It is not clear whether these factors are the cause or result
of disease state development (Liu et al., 2011). More obvious cause-and-effect examples
are mutations in proteins such as APP, Presinilin (1 and 2) and Tau (Bull et al., 2012;
Multhaup et al., 2015; Moustafa et al., 2018). APP is a single pass transmembrane
protein enriched at synapses (Multhaup et al., 2015). Many functions have been proposed
for APP including participation in synapse formation, long range signaling and axonal
transport (Multhaup et al., 2015). As part of its function APP is cleaved by α-, β- and γsecretases (Multhaup et al., 2015). In the non-disease state, cleavage by α- and βsecretase allows for normal function (Multhaup et al., 2015). APP mutations in secretase
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recognition sites leaves it more vulnerable to disease state γ-secretase cleavage
(Multhaup et al., 2015).
The Presinilin genes encode components of the γ-secretase complex which
participates in the disease state cleavage of APP into the pathogenic peptide Aβ (Hutton
and Hardy, 1997). Mutations in Presinilin-1 have been proposed to increase γ-secretase
activity and the generation of Aβ (Hutton and Hardy, 1997; Sun et al., 2017). Tau
missense mutations can impair microtubule binding and silent mutations affect alternate
splicing of Tau thereby shifting isoform expression (Yen et al., 1999). Tau plays an
important role in the regulation of axonal transport and disruption of its functions leads to
impaired cargo transport (Heins et al., 1991; LaPointe et al., 2009; Kanaan et al., 2012).

1.2 Axonal Transport
1.2.1 Fast Axonal Transport
The first observation of axonal transport was made four decades after Ramón y
Cajal received his Nobel Prize (Stenoien and Brady, 1999). Experiments by Weiss and
Hiscoe showed that materials manufactured in the neuronal cell body were essential to
the maintenance of the axon (Weiss and Hiscoe, 1948). When bulk flow was first
described, it was found to move at 1-2 mm/day (Stenoien and Brady, 1999). While this
movement fulfilled some of the requirements for axonal maintenance, it quickly became
apparent that the slow flow of material could not keep up with the fast signals that were
known to travel down the axon (Stenoien and Brady, 1999). Twenty years of further
study showed that a component of this bulk flow moved at much faster rates (up to 400
mm/day) in both the anterograde and retrograde directions (Stenoien and Brady, 1999).
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Fast axonal transport is associated with membrane bound proteins and
organelles. The size of the transported proteins/organelles has been shown to dictate the
rate of transport with larger organelles such as mitochondria moving as slow as 50
mm/day (Stenoien and Brady, 1999). Not even the slowest form of fast axonal transport
could be explained by the flow of material which governs slow axonal transport. As
evidence for some directed transport mechanism, it was found that disruption of the
microtubule network inhibited fast axonal transport (Stenoien and Brady, 1999).
By the mid 1980s the idea of motor mediated movement was not new though it
had yet to be linked to fast axonal transport (Stenoien and Brady, 1999). Muscle myosin
was first described in 1864 by Wilhelm Kühne (Hartman and Spudich, 2012) and,
Gibbons and Rowe showed that dynein isolated from cilia had ATPase activity (Gibbons
and Rowe, 1965). It was known that myosin interacted with actin and dynein with
microtubules (Stenoien and Brady, 1999). Therefore, in light of the microtubule
dependence of fast axonal transport it was hypothesized that dynein was involved
(Stenoien and Brady, 1999). Attempts were made to identify dynein in the brain (Murphy
et al., 1983) but ATP analog studies showed that a third motor was required for cargo
transport

(Stenoien

and

Brady,

1999).

The

inhibitory

analog,

5'-adenylyl-

imidodiphosphate (AMP-PNP) has a mild effect on both myosin and dynein but, once
perfused into squid axoplasm, AMP-PNP completely stopped fast axonal transport (Vale
et al., 1985; Stenoien and Brady, 1999). This high affinity for the microtubule in the
presence of AMP-PNP was used to purify the motor now called kinesin (Vale et al.,
1985).

17

1.2.2 Kinesin Motors
Experiments in the early 1980s pointed to an as yet unknown ‘translocator’
which moved microtubule associated cargo in the axon, specifically squid axoplasm
(Brady et al., 1982; Allen et al., 1985). Vale purified a novel ATPase from axoplasm and
bovine brain which was able to slide microtubules in gliding filament assays and move
beads along microtubules in motility assays (Vale et al., 1985). The word kinesin was
derived from the Greek kinein (to move) (Vale et al., 1985) and this first kinesin became
the founding member of a large class of proteins (Hirokawa et al., 2009).
There are fourteen kinesin families, kinesin-1 through kinesin-14, designated
based on shared features determined by sequence alignment and phylogenetic analysis
(Figure 1.5) (Hirokawa et al., 2009). Regardless of family, all kinesins have ATP
hydrolyzing motor domains and coiled-coil domains which facilitate dimerization (Figure
1.5) (Vale, 2003; Hirokawa et al., 2009).
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Figure 1.5: Families and structures of mammalian kinesins.
a) A phylogenetic tree of all 45 kinesins (KIFs) grouped into 14 families (kinesin-1 to 14). b) Domain structures of the major kinesins. In general, kinesins comprise a kinesin
motor domain and a coiled-coil domain. There are also gene specific domains, such as the
pleckstrin homology (PH), the CAP-Gly domain (a conserved, Gly-rich domain of ~42
residues found in some cytoskeleton-associated proteins) and WD40 repeats. The
fourteen families of kinesins can be grouped into N-kinesins, M-kinesins and C-kinesins,
which contain their motor domain at the amino terminus, in the middle or at the carboxyl
terminus, respectively. N-kinesins are plus end-directed, C-kinesins are minus enddirected and M-kinesins depolymerize microtubules. The three types of kinesin are
grouped as indicated. Figure and legend adapted from Hirokawa et al. (2009). Reprinted
by permission from Copyright Clearance Center: Springer Nature, Nature Reviews
Molecular Cell Biology, Kinesin superfamily motor proteins and intracellular transport.
Hirokawa, N., Noda, Y., Tanaka, Y., and Niwa, S. (2009).
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The motor domain position of a kinesin can give some insight into its function.
Kinesins with N-terminal motor domains are plus end directed, C-terminal motor
domains are minus end directed and kinesins with motor domains in the middle of their
sequence act to depolymerize microtubules (Hirokawa et al., 2009). Of the fourteen
families, there are three major players involved in axonal cargo transport: kinesin-1, -2
and -3 though kinesin-4 has been found to associate with cargo as well (Hirokawa et al.,
2009).
In vertebrates, kinesin-1 is a heterotetramer comprised of two heavy chains
(kinesin heavy chain, KHC) containing the motor and coiled-coil domains, and two light
chains (kinesin light chains, KLC) which bind to the C-termini of the KHCs and facilitate
cargo binding (Vale, 2003). Vertebrates have three KHC genes, two are ubiquitously
expressed while the third is neuronally expressed (Brady and Morfini, 2017). Two KLCs
(KLC1 and 2) are neuronally expressed (Brady and Morfini, 2017). Combinations of
heavy and light chains allow for at least six different kinesin-1 holoenzymes (Brady and
Morfini, 2017). In addition to different KLCs, a number of adaptor proteins have been
identified for kinesin-1. They include: Milton and Miro which appear to facilitate
mitochondrial binding (Wang and Schwarz, 2009), unc-76 from C. elegans (Fasiculation
and elongation protein zeta 1 (FEZ1) in humans) which allows binding to presynaptic
vesicles (Toda et al., 2008) and Jun N-terminal kinase (JNK) interacting protein 1 (JIP1)
which binds to APP transporting vesicles (Inomata et al., 2003).
Given the importance of kinesin-1, the motor must be carefully regulated to
ensure the most efficient delivery of cargo. In addition to autoinhibition, the motor can be
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regulated by phosphorylation, MAPs and the microtubule track on which it walks
(Verhey and Hammond, 2009).
In the absence of cargo, kinesin-1 is autoinhibited by interactions between the
motor domain, KHC tail domains and the KLC (Figure 1.6) (Verhey and Hammond,
2009). The tail domain contains the conserved sequence QIAKPIRP which has been
shown to interact with the motor domain preventing nucleotide exchange (Figure 1.6)
(Verhey and Hammond, 2009). Autoinhibition is further regulated by phosphorylation.
Analytical ultracentrifugation experiments show that JNK3 mediated phosphorylation of
serine 175 stabilizes kinesin-1’s autoinhibited state (Figure 1.6) (DeBerg et al., 2013).
Both cargo binding and motor-adaptor protein interactions (FEZ1 and JIP1) have been
shown to relieve autoinhibition (Figure 1.6) (Verhey and Hammond, 2009).
Phosphorylation of KLC has also been shown to regulate motor-cargo interactions
and therefore cargo delivery. There are a number of kinases that act on KLC including
extracellular-signal regulated kinase (ERK) and GSK3β (Morfini et al., 2002; Vagnoni et
al., 2011). ERK phosphorylates KLC serine 460 (Figure 6) (Vagnoni et al., 2011).
Phosphorylation of this site selectively prevents KLC interactions with calsyntenin 1 but
not other adaptors such as JIP1 (Vagnoni et al., 2011). Calsyntenin 1 is a cadherin-like
protein which facilitates kinesin-1 interactions with cargo and regulates microtubule
polarity during axonal development (Lee et al., 2017). Interestingly, adaptor protein
phosphorylation also regulates interactions with the motor (Figure 1.6) (Chua et al.,
2012). GSK3β is thought to have multiple recognition sites on KLC (Figure 1.6) (Morfini
et al., 2002). When perfused into the axoplasm, active GSK3β slows anterograde
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transport (Morfini et al., 2002). Spatial control of kinesin-1 holoenzyme phosphorylation
regulates both the activation of the motor and its interaction with cargo.
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Figure 1.6: Kinesin-1 activity is regulated by autoinhibition, phosphorylation and
adaptor proteins/cargo.
Kinesin-1 (red/blue) is autoinhibited in a folded conformation though interactions
between the KHC (red) tail conserved sequence QIAKPIRP and the KLC (blue) with the
motor domains. Phosphorylation (gray) of the motor domain at serine 175 stabilizes this
autoinhibited conformation. Phosphorylation of the KLC disrupts interactions with
specific adaptors. Kinesin-1 autoinhibition can be relieved by dephosphorylation of
serine 175 and the KLC, cargo binding and/or binding of adaptor proteins (FEZ1 and
JIP1) to the KLC and KHC respectively. Phosphorylation of adaptor proteins (FEZ1) has
been shown to facilitate motor-adaptor interactions. Figure and legend created based on
Morfini et al. (2002), Verhey and Hammond, (2009), Vagnoni et al. (2011), Chua et al.
(2012) and DeBerg et al. (2013).
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1.2.3 Neuronal Tubulin
Though evidence for microtubules was first found in early electron micrographs,
it was not till 1963 that they were recognized as distinct structural elements (van de
Willige et al., 2016). Microtubules are polymers of αβ-tubulin heterodimers that
assemble to form a hollow tube of on average 13 protofilaments (Yu et al., 2015; van de
Willige et al., 2016). Both α- and β-tubulin are globular with disorganized, negatively
charged C-terminal tails (CTT) (Yu et al., 2015). Microtubule polymerization is
facilitated by β-tubulin GTP binding (Desai and Mitchison, 1997). Tubulin dimers
polymerize with a fixed α-β polarity and new dimers are added to the β-tubulin end (plus
end) of the growing microtubule (Figure 1.7) (Geyer et al., 2015; van de Willige et al.,
2016). Microtubules are considered to have dynamic instability because of their ability to
undergo rapid rounds of growth and shortening (van de Willige et al., 2016). A growing
microtubule generally has a lattice of predominantly GDP bound dimers and a cap of
predominantly GTP dimers (Figure 1.7) (Geyer et al., 2015; van de Willige et al., 2016).
This GTP cap contributes to the stability of the microtubule and GTP hydrolysis in the
cap is one of the factors that contributes to depolymerization (Desai and Mitchison,
1997). It has been shown that the nucleotide bound state affects the structure of the
dimers in the lattice (Geyer et al., 2015). GTP bound tubulin has a compacted α-tubulin
subunit and GTP hydrolysis relieves this compaction (Geyer et al., 2015). Interestingly,
some microtubule bound proteins track the GTP cap by recognizing these conformational
changes (Geyer et al., 2015).
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Figure 1.7: Tubulin dimer nucleotide exchange and microtubule polymerization.
A) Both α- and β-tubulin bind GTP however, nucleotide exchange by β-tubulin (in the E
site) drives microtubule dynamics. B) While GTP is bound to the E site (yellow βtubulin), polymerization occurs and as long as the growing microtubule maintains a GTP
cap growth will continue. GTP hydrolysis (blue β-tubulin) within the lattice is not
sufficient to lead to catastrophe though this hydrolysis does increase the likelihood of
lattice defects and once hydrolysis occurs in the GTP cap, catastrophe is inevitable
(Alushin et al., 2014). Figure and legend adapted from Alushin et al. (2014). Reprinted
from Cell, 157/5, Alushin, G.M., Lander, G.C., Kellogg, E.H., Zhang, R., Baker, D., and
Nogales, E., High-resolution microtubule structures reveal the structural transitions in
alphabeta-tubulin upon GTP hydrolysis, Pages No. 1117-1129, Copyright (2014) with
permission from Elsevier.
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As previously discussed, kinesin-1 is regulated by autoinhibition, phosphorylation
and adaptor protein/cargo binding. However, the microtubule track is itself a major point
at which regulation of axonal transport takes place. Microtubule polarity ensures that
kinesin-1 and other major kinesins move cargo towards the synapse (anterograde) while
the minus end directed motor cytoplasmic dynein moves cargo towards the cell body
(retrograde) (Stenoien and Brady, 1999).
In humans, nine α-tubulin and ten β-tubulin genes have been identified (Aiken et
al., 2017). In the brain, βIVa is the predominant β tubulin isoform expressed though βIII,
βIIa and βIIb are also expressed (Leandro-Garcia et al., 2010). βI tubulin is found in all
tissues (Leandro-Garcia et al., 2010). Of the nine α-tubulin isoforms, α1 and α8 are of
great importance in neural development and axon growth (Romaniello et al., 2015).
In addition to heterodimer diversity, tubulin is subject to a plethora of post
translational

modifications

including tyrosination, detyrosination, glutamylation,

phosphorylation, and glyclation (Figure 1.8) (Yu et al., 2015). These modifications are
often enriched in different cell types and cell cycle time points (Yu et al., 2015). In the
growth cone, dynamic microtubules are enriched in tyrosination but the stable
microtubules of the axon are detyrosinated, acetylated and glutamylated (Yu et al., 2015).
Tyrosination/detyrosination takes place on α-tubulin CTT (Figure 1.8) (Yu et al., 2015).
α-Tubulin is initially expressed with a C-terminal tyrosine which can be removed and
reattached as needed (Yu et al., 2015). Detyrosination exposes a glutamic acid (E-hook)
and can be made permanent by removal of this E-hook (Yu et al., 2015).
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In vivo, kinesin-1 has been shown to prefer binding detyrosinated microtubules (Dunn et
al., 2008). In vitro experiments confirmed this increased affinity along with a slightly
increased velocity though no change in run length was observed (Kaul et al., 2014).
α-Tubulin is also acetylated on its lumenal surface at lysine 40 while β tubulin is
acetylated at lysine 252 (Figure 1.8) (Yu et al., 2015). In vitro experiments show that
compared to deactylated microtubules, lysine 40 acetylation does not affect kinesin-1 run
length, velocity or affinity for the microtubule (Kaul et al., 2014). It is to be noted that
kinesin-1 does have a longer run length on acetylated versus detyrosinated microtubules
(Kaul et al., 2014). On acetylated and detyrosinated microtubules as found in the axon,
kinesin-1 has both increased affinity and run length compared to tyrosinated, deacetylated
microtubules (Kaul et al., 2014). More recent work suggests that this increased run length
observed for kinesin-1 on acetylated microtubules is due to increased microtubule
bundling and therefore kinesin-1 binding site availability (Balabanian et al., 2017). The
acetylated, detyrosinated microtubules found in the axon enhance kinesin-1 motility
which in turn allows for more efficient cargo transport. Interestingly, detyrosination has
been shown to act as an axonal targeting cue for kinesin-1 (Konishi and Setou, 2009).
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Figure 1.8: Posttranslational modifications of the αβ tubulin heterodimer.
A. ribbon representation of the tubulin heterodimer (green, α-tubulin; blue, β-tubulin)
with CTT shown using sequences for the α1A and βIVb tubulin isoforms. Sites of
acetylation (magenta) and polyamination (dark blue) are shown in stick representation.
The α-tubulin C-terminal tyrosine (orange) is subject to enzymatic removal
(detyrosination/tyrosination). Tail glutamates are subject to glutamylation and
glycylation. B. Zoomed-in view showing the acetylated β-tubulin lysine 252. C. and D.
view of the α-tubulin (C) and β-tubulin (D) longitudinal interfaces showing the position
of mapped polyamination sites as dark blue sticks. α-Tubulin lysine 40 is shown in stick
representation (magenta). Am, amination. Ac, acetylation. Figure and legend adapted
from Yu et al., (2015) in accordance with the Creative Commons Attribution license.
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1.2.4 Neuronal MAPs
Microtubule associated proteins (MAPs) as their name suggests, bind to the
microtubule cytoskeleton. These proteins include the microtubule tip tracking proteins
(+TIPs), MAP1, MAP7, MAP2 and MAPT (Tau).
+TIPs track the growing end of the microtubule. They include the end binding
proteins (EB 1-3), EB-dependent +TIPs and EB-independent +TIPs (van de Willige et
al., 2016). EBs track the GTP cap by recognizing structural changes in the tubulin dimer
upon GTP binding (van de Willige et al., 2016). EB3 is upregulated during neurogenesis
however, neurite growth and axon formation have been shown to depend on both EB1
and 3 in neuroblastoma cells and Drosophila (van de Willige et al., 2016). Depletion of
EB1 in axonal development leads to microtubule splaying and disorganization (van de
Willige et al., 2016). While tracking the plus end, EBs serve as scaffolds for other +TIPs.
The higher affinity of EB1/3 for the microtubule has been hypothesized to facilitate
scaffold maintenance in the growing axon (van de Willige et al., 2016). Proteins that
scaffold with EB1/3 have conserved binding motifs such as an SxIP (serine/threonine-xisoleucine/leucine-proline) or CAP-gly (cytoskeletal-associated protein glycine rich) (van
de Willige et al., 2016). Proteins with SxIP and CAP-gly sequences participate in the
maintenance of the axonal cytoskeleton facilitating both anterograde and retrograde
transport (van de Willige et al., 2016).
MAP1 A and B were initially characterized as microtubule stabilizers. Early
reports suggested that MAP1B localizes to the tips of growing axons (Black et al., 1994).
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In mouse dorsal root ganglion cells, knock out of MAP1B led to axon turning defects and
the complete deletion of MAP1B has been shown to prevent development of the corpus
callosum (Halpain and Dehmelt, 2006). MAP1B is therefore involved in the cytoskeletal
regulation and axonal development.
As with the other MAPs above, MAP7 (ensconsin) was first described as a
microtubule stabilizing protein (Bulinski and Bossler, 1994). Since its characterization, it
has been demonstrated that MAP7 plays a role in activating kinesin-1 in neurons through
interactions between the kinesin-1 ‘hinge’ region and MAP7 N-terminal (Barlan et al.,
2013). Though MAP7 activates kinesin-1, it has been shown to inhibit kinesin-3 (Monroy
et al., 2017). This preferential activation/inhibition further demonstrates the complexity
of cargo transport regulation.
Of the MAPs, MAP2 and Tau are the most frequently studied. MAP2 has three
isoforms (a, b and c) whose expression is developmentally regulated (Tucker et al.,
1988). MAP2c is expressed during development while MAP2a/b are expressed in mature
neurons (Dehmelt and Halpain, 2005). MAP2c has been shown to be sufficient to induce
neurite formation (Dehmelt and Halpain, 2005). This is thought to be due to its ability to
bind both microtubules and actin thereby coordinating microtubule and actin dynamics
(Dehmelt and Halpain, 2005). As the neuron develops, MAP2 is excluded from the
forming axon and in mature neurons, MAP2 localizes to dendrites (Dehmelt and Halpain,
2005). Conversely, Tau is confined to the forming axon and is excluded from dendrites
(Dehmelt and Halpain, 2005). Both MAP2 and Tau have similar microtubule binding
repeat regions, have been shown to act as scaffolding proteins and are known to bundle
microtubules (Dehmelt and Halpain, 2005). The segregation of MAP2 and Tau must
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therefore relate to their functions in the dendrite and axon respectively. Tau has been
shown participate in many aspects of axonal transport including the regulation of kinesin1 and -3 (Lessard and Berger; Stern et al., 2017). A number of neurodegenerative
diseases, grouped as Tauopathies, develop due to aberrant expression or regulation of Tau
within the neuron (LaPointe et al., 2009; Stern et al., 2017; Yin et al., 2017).
1.3 Tau
1.3.1 Roles of Tau in Axonal Transport
Tau was first identified in 1975 and at the time, it was thought to be a
microtubule nucleating factor (Weingarten et al., 1975). Later work found that Tau bound
the microtubule surface with high affinity through a number of microtubule binding
repeats which each have a weak affinity for the microtubule (Butner and Kirschner,
1991).
Since its discovery, Tau has been shown to have many roles beyond microtubule
nucleation. This includes roles within the axon such as regulation of microtubule
dynamics, participation in signaling cascades and inhibition of kinesin-1 motility (Stern
et al., 2017). While Tau is generally thought to stabilize microtubules, its function in the
regulation of microtubule dynamics is more complex. Work done by Panda et al. shows
that Tau affects specific aspects of microtubule growth and shortening (Panda et al.,
2003). 4RL-Tau reduces the rate of shortening while 3RL-Tau has no effect (Panda et al.,
2003). However, both isoforms increase microtubule growth and reduce dynamicity
(Panda et al., 2003).
Tau participates in signaling cascades in a number of ways. Tau has been shown
to inhibit the deacetylation activity of histone deacetylase 6 (HDAC6) which acts on
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microtubules (Perez et al., 2009). Additionally, Tau’s phosphatase activating domain
(PAD) has been shown to play a role in the regulation of bulk cargo movement through
the axon (LaPointe et al., 2009). The PAD has been shown to act in the activation of the
protein phosphatase 1 (PP1) which in turn leads to the activation of GSK3β (Morfini et
al., 2002; Kanaan et al., 2011; Kanaan et al., 2012). Outside of the axon in the dendrite,
Tau acts as a scaffolding protein to mediate the interaction between Fyn kinase and post
synaptic density 95 (PSD95) in the disease state (Ittner et al., 2010). This interaction
leads to the phosphorylation and toxic activation of the N-methyl-D-aspartate (NMDA)
receptor (Ittner et al., 2010). In addition to all of the above roles, Tau has been found in
the nucleus where it is thought to protect DNA (Sultan et al., 2011).
1.3.2 Regulation of Tau Isoform Expression
There are six human Tau isoforms (Figure 1.9) which arise from the alternative
splicing of a single Tau gene on chromosome 17 (Andreadis, 2005). All the isoforms
have a PAD and proline rich region (PRR) while isoforms differ based on number of
acidic inserts (0-2) and microtubule binding repeats (3-4) (Figure 1.9) (Stern et al., 2017).
In the mapT gene, exon 10 encodes the second microtubule binding repeat and regulation
of exon 10 inclusion controls 3 repeat (3R)- versus 4R-Tau isoform expression. This
regulation occurs developmentally and 3R isoforms are exclusively expressed in the
developing brain. In the adult brain 3R and 4R isoforms are expressed equally
(Andreadis, 2005; Yin et al., 2017). Splicing of exons 2 and 3 controls the number of
acidic inserts (AI) and give rise to short (0 AI), intermediate (1 AI) and long (2 AI)
isoforms (Yin et al., 2017).
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Acidic Inserts

Microtubule Binding Repeats
4RL-Tau
3RL-Tau
4RM-Tau
3RM-Tau
4RS-Tau
3RS-Tau

Phosphatase Activating
Domain

Proline Rich Region

Figure 1.9 Tau isoforms.
Six Tau isoforms are expressed in the adult brain as the result of alternative splicing
of the gene mapT (Ballatore et al., 2007). All isoforms have a phosphatase activating
domain (purple) and a proline rich region (blue). The isoforms differ based on
number of acidic inserts (green; 0, 1 or 2) and microtubule binding repeats (red; 3 or
4). Inclusion of acidic inserts and the second microtubule binding repeat is regulated
by alternative splicing of exons 2, 3 and 10. Figure and legend based on Ballatore et
al., (2007).
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The regulation of exon 10 splicing is critically important for the maintenance of
the neuron. Defects in exon 10 splicing lead to shifts in the ratio of 3R vs 4R Tau isoform
expression (Yin et al., 2017). In frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17), mutations in the Tau gene result shifts in 3R or 4R isoform
expression (Yin et al., 2017). In Down Syndrome, trisomy of chromosome 21 leads to the
overexpression of the kinase dual-specificity tyrosine-phosphorylated and regulated
kinase 1A (Dyrk1A) (Yin et al., 2017). Dyrk1A has mainly nuclear expression and has
been shown to co-localize with splicing factors (Yin et al., 2017). Furthermore Dyrk1A
phosphorylates serine/arginine rich factor 55 (SRp55) (Yin et al., 2017). SRp55 has been
shown to regulate the inclusion of exon 10 (Yin et al., 2012; Qian et al., 2013). SRp55
promotes exon 10 inclusion and phosphorylation by Dyrk1A leads to down regulation of
SRp55 activity and increased 3R-Tau expression (Yin et al., 2017). Alternatively,
inhibition of Dyrk1A leads to increased 4R-Tau expression (Yin et al., 2017). In AD,
calpain activation has been shown lead to increased Dyrk1A cleavage at the C-terminus
(Jin et al., 2015). This leads to increased Dyrk1A activity which is correlated with shifts
in isoform expression (Jin et al., 2015). During mouse development, Dyrk1A expression
has been shown to decrease from postnatal day (P) 5 to P35 corresponding with a shift
from 3R to 4R isoform expression (Yin et al., 2017).
Dyrk1A action is not the only means by which Tau isoform expression is
regulated. Transactive DNA-binding protein of 4 kDa (TDP-43) has been shown to
promote exon 10 inclusion (Gu et al., 2017). Interestingly, TDP-43 has been shown to
aggregate in the cytoplasm of AD patients (Gu et al., 2017). Unlike Dyrk1A activity,
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increased TDP-43 activity leads to increased 4R isoform expression (Gu et al., 2017).
Shifts of to either extreme of isoform expression are detrimental for the cell and are a
hallmark of disease development.
1.3.3 Post-translational Modifications of Tau
Tau is subject to a number of post-translational modifications (PTMs) including
methylation, acetylation, ubiquitination, O-GlcNacylation and phosphorylation (Figure
1.10) (Morris et al., 2015). Of these PTMs, phosphorylation is the most abundant though
work has been done with acetylation and its role in disease state development (Cohen et
al., 2011; Morris et al., 2015; Carlomagno et al., 2017). Acetylation has been shown to
inhibit Tau-microtubule interactions and promote filament formation (Cohen et al.,
2011). Recently, disease state acetylation of lysine 321has been shown to promote
phosphorylation of serine 324 (Carlomagno et al., 2017). This link between PTMs
highlights the need to further study non-phosphorylation PTMs in Tau function.
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Figure 1.10 Domain structure of 4RL-Tau showing the positions of many PTMs.
Tau is an incredibly modified protein with 85 proposed or identified phosphorylation
sites. Figure and legend adapted from Morris et al. (2015). Reprinted by permission from
Copyright Clearance Center: Springer Nature, Nature Neuroscience, Tau posttranslational modifications in wild-type and human amyloid precursor protein transgenic
mice, Morris, M., Knudsen, G.M., Maeda, S., Trinidad, J.C., Ioanoviciu, A., Burlingame,
A.L., and Mucke, L. (2015).
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As the most abundant PTM, it is not surprising that Tau has 85 proposed or
identified phosphorylation sites (Martin et al., 2013b). Most of these sites have been
identified in the disease state and cluster around the proline rich region and MBRs
(Martin et al., 2013b). It has been shown that phosphorylation in and around the MBR
reduces Tau’s affinity for the microtubule surface (Biernat et al., 1993). As indicated by
the large number of phosphorylation sites, Tau is phosphorylated by a number of kinases.
These include the serine/threonine kinases GSK3β, CDK5, PKA and the tyrosine kinases
Fyn, Lck and Abl (Martin et al., 2013b).
Initially, GSK3β was thought to be Tau protein kinase 1 before Ishiguro proved
that these kinases were identical (Ishiguro et al., 1993). Both GSK3β and CDK5
phosphorylate Tau at many serine/threonine sites including serine 202/threonine 205
(widely known as the AT8 epitope) (Goedert et al., 1995; Wada et al., 1998). Disease
state phosphorylation is exacerbated by the fact that phosphorylation by one kinase
primes other sites (Hanger and Noble, 2011). For example, priming phosphorylation of
serine 235 and serine 404 by CDK5 and other kinases, allows GSK3β to phosphorylate
Tau at serine 396 and serine 400 (Hanger and Noble, 2011). PKA phosphorylation also
serves to prime GSK3β sites (Hanger and Noble, 2011). PKA phosphorylation of serine
214 allows GSK3β phosphorylation of serines 175, 199, 210 and threonine 205 (Hanger
and Noble, 2011). This paints a complex picture of hyperphosphorylation which requires
the coordinated action of multiple misregulated kinases.
The Src family kinases have been shown to phosphorylate Tau at all five
tyrosines (18, 29, 197, 310 and 394) (Lee et al., 1998; Martin et al., 2013b). The
interactions between Tau and these kinases occur away from the microtubule surface
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because Src family kinases are membrane anchored (Lee et al., 1998). PXXP motifs in
Tau’s proline rich region, allow interactions with Src homology 3 domains (Lee et al.,
1998). Of the Src kinases that phosphorylate Tau, Fyn is of interest because it has been
shown to predominantly phosphorylate Tau at tyrosine 18 (Y18). Both Tau and Fyn are
present in the developing axon and the loss of Fyn leads to loss of axon extensions in Fyn
knockout mice (Lee et al., 1998). Fyn is itself subject to phosphorylation on tyrosine
residues (Vacaresse et al., 2008). Tyrosine phosphorylation in the C-terminal inhibits Fyn
activity while auto-phosphorylation at tyrosine 416 and the action of protein tyrosine
phosphatase to remove the inhibitory phosphorylation in response to external growth
cues, activates the kinase and allows it to then phosphorylate Tau and other targets
(Vacaresse et al., 2008). Tau Y18 is phosphorylated in both the disease and non-disease
states (Lee et al., 1998; Martin et al., 2013b) and Fyn has been shown to associate with
neurofibrillary tangles in the disease state (Lee et al., 2004). The case of tyrosine 18
phosphorylation is unique because of it has been shown to shield the PAD in the disease
state (Kanaan et al., 2012) and to potentially stabilize a non-disease sate, solution based
dynamic folded conformation of Tau (Jeganathan et al., 2006).
Tau regulates axonal transport in a number of ways (discussed above) including
through participation in signaling cascades. Signaling cascade participation is mediated
by Tau’s PAD domain which has been shown to participate in the activation of GSK3β
(Kanaan et al., 2012). Tyrosine 18 is the last residue in the PAD and its phosphorylation
prevents Tau from participating in GSK3β activation (Kanaan et al., 2012). In fact, the
PAD fragment has been shown to inhibit the bulk flow of cargo in the axoplasm while
tyrosine 18 phosphorylated PAD did not have the same effect (Kanaan et al., 2012)
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highlighting a role for non-disease state phosphorylation events in the maintenance of
axonal transport.
As with all phosphorylation events, Tau phosphorylation is antagonized by the
action of phosphatases. These include, PP1, protein phosphatase 2A (PP2A) and protein
tyrosine phosphatases (Martin et al., 2013a). These phosphatases control the action of the
kinases that phosphorylate Tau as well as the phosphorylation of Tau itself (Martin et al.,
2013a). In the disease state, phosphatase activity is greatly reduced further exacerbating
the activity of the kinases which ultimately phosphorylate Tau (Martin et al., 2013a).
1.3.4 Tau and Kinesin
MAP inhibition of motor motility was first demonstrated in 1989 (von Massow
et al., 1989). In 1991, Heins et al. showed that both MAP2 and Tau inhibited kinesin
dependent motility (Heins et al., 1991). This gave rise to a model where Tau and other
MAPs act as obstacles for kinesin thereby reducing kinesin runlength (Seitz et al., 2002).
TIRF assays showed that this was indeed the case as both MAP2 and Tau inhibited
kinesin runlength (Seitz et al., 2002). These results agreed with previous work
demonstrating that over expression of Tau in neuronal cell lines inhibits movement of
kinesin cargo (Ebneth et al., 1998). Interestingly, TIRF assays performed by Seitz et al.
showed differences in tau isoform inhibition where 3RS-Tau was more inhibitory then
4RL-Tau (Seitz et al., 2002).
Reports of MAP-motor inhibition suggested that both kinesin and dynein were
inhibited by Tau (Trinczek et al., 1999). However, more recent work demonstrated that
both 3RS- and 4RL-Tau inhibited kinesin-1 at multiple concentrations while kinesin-2
and dynein were not affected (Dixit et al., 2008; Hoeprich et al., 2014). This work
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showed Tau’s preferential inhibition of kinesin-1 motility. TIRF assays also
demonstrated Tau patch formation i.e. cooperative binding on the microtubule surface in
accordance with earlier work (Ackmann et al., 2000; Dixit et al., 2008).
Highlighting the interconnectivity of the axonal transport system, in addition to
Tau isoform differences, the microtubule lattice has been shown to affect the isoforms’
ability to inhibit kinesin-1 (McVicker et al., 2011). McVicker et al. (2011) showed that
both 3RS- and 4RL-Tau inhibition of kinesin-1 motility was reduced on GMPCPP
microtubules compared to paclitaxel stabilized microtubules. Additionally complicating
the idea of Tau inhibition, increases in motor velocity were observed in the presence of
both isoforms though kinesin-1 showed a greater increase in velocity in the presence of
4RL-Tau on paclitaxel stabilized microtubules (McVicker et al., 2011). This paints a
picture of Tau isoform and microtubule lattice regulation instead of straight inhibition of
kinesin-1 motility.
For twenty-three years it was thought that Tau and other MAPs were immobile
while bound to the microtubule (Ackmann et al., 2000; Dixit et al., 2008). However,
further work showed that Tau is able to bind both statically and diffusively to the
microtubule surface (Figure 1.11) (Hinrichs et al., 2012). This study highlighted a
possible mechanism by which the high concentrations of Tau found in the axon do not
impede cargo delivery in non-disease state conditions. However, it did not explain the
differences in Tau isoform ability to regulate kinesin-1 motility.
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Figure 1.11 Tau diffuses along the microtubule surface.
A) Frames of a labeled 4RL-Tau molecule (green) moving along a Cy5-labeled
microtubule (red) in the absence of ATP. Time intervals were as indicated. B)
Kymograph showing the diffusive behavior of the event pictured in A. Figure and
legend adapted from Hinrichs et al., (2012) in accordance with the Creative
Commons Attribution license.
.
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Furthering the observation that Tau binds the microtubule in a static-diffusive
state equilibrium, 3RS- and 4RL-Tau were observed to have different binding equilibria
(McVicker et al., 2014). 3RS-Tau binds more statically that 4RL-Tau on paclitaxel
microtubules (McVicker et al., 2014). This suggested that 3RS-Tau was more inhibitory
to kinesin-1 because of its shift towards static binding. This hypothesis was further
supported when both isoforms were observed to shift towards diffusive binding on
GMPCPP microtubules where previous work demonstrated that Tau is less inhibitory to
kinesin-1 motility (McVicker et al., 2014).
While this work takes into account the nucleotide bound state of the lattice,
questions remain about the involvement of lattice and Tau PTMs in the regulation of Tau
behavior. Recent work has begun to answer these questions. Non-disease state
phosphorylation of tyrosine 18 has been shown to regulate 3RS-Tau’s binding
equilibrium (Stern et al., 2017). Work with acetylation demonstrated that Tau is
insensitive to this microtubule PTM though it was observed to favor highly curved
microtubule sections (Balabanian et al., 2017).
1.3.5 Tau Structure
In 1975 when Tau was first identified, it was found to be heat stable
(Weingarten et al., 1975). This property surprised the authors at the time and was the first
identification that Tau did not have a tertiary structure. Circular dichroism assays
comparing Tau to myoglobin revealed that Tau had no significant α-helical or β-sheet
structure confirming the 1975 observations (Cleveland et al., 1977). Almost upon
discovery, the challenge to understand Tau structure was made apparent.
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By 1988, neuronal microtubules had been observed to have crosslinks comprised
of MAP1 and MAP2 but the structure of Tau remained unknown though its role in the
disease state was firmly established (Hirokawa et al., 1988). Deep-etch cryo-EM studies
showed that a portion of the Tau molecule extends away from the microtubule surface
(Hirokawa et al., 1988). Other cryo-EM studies that did not rely on pelleting, showed that
Tau bound to microtubules results in a ‘fuzzy’ microtubule coating (Al-Bassam et al.,
2002; Santarella et al., 2004). These studies used helical reconstruction and Tau labeling
techniques to determine that Tau binds along protofilament ridges potentially with
binding sites at the α-tubulin subunits (Al-Bassam et al., 2002; Santarella et al., 2004).
Current work by the Nogales group, refines previous cryo-EM work confirming Tau
binding on microtubule protofilaments with microtubule binding repeats binding in
tandem (Kellogg et al., 2018). This binding occurs along tubulin heterodimers (Kellogg
et al., 2018) and explains Tau’s ability to regulate microtubule dynamics by crosslinking
dimers. Together, these studies elucidate Tau structure though none of these studies
account for the dynamic structural changes which the ‘fuzzy’ microtubule coat indicates.
In addition to the investigation of Tau’s bound structure, solution based study of
Tau confirmation using NMR, bulk FRET and single molecule FRET studies, show that
Tau has a dynamic folded confirmation (Figure 1.12) (Jeganathan et al., 2006; ElbaumGarfinkle and Rhoades, 2012). These two studies differ in their placement of the N- and
C-termini relative to the MBRs though they both agree in the folded nature of Tau in
solution (Figure 1.12) (Jeganathan et al., 2006). Further work with disease state
phosphorylation events showed compaction of Tau’s solution based folded confirmation
(Jeganathan et al., 2008).
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Figure 1.12 Structures of Tau in solution.
Tau has been shown to have a dynamic folded conformation in solution. A) NMR and
bulk FRET studies were used to generate this paperclip-like folded conformation where
the C-terminal interacts with the microtubule binding repeats and the N-terminal. The
overall conformation is stabilized by interactions between the N- and C-termini. Figure
and legend reprinted with permission from Jeganathan, S., von Bergen, M., Brutlach, H.,
Steinhoff, H.J., and Mandelkow, E. (2006). Global hairpin folding of tau in solution.
Biochemistry 45, 2283-2293. Copyright (2006) American Chemical Society. B) Single
molecule solution based FRET was used to generate this conformation of Tau in the
absence of heparin (watermark) where both the N- and C-termini interact with the
microtubule binding repeats to stabilize this folded conformation. In the presence of
heparin, which promotes Tau aggregation, these interactions are greatly reduced. Figure
and legend reprinted with permission from Elbaum-Garfinkle, S., and Rhoades, E.
(2012). Identification of an aggregation-prone structure of tau. J. Am. Chem. Soc. 134,
16607-16613. Copyright (2012) American Chemical Society.
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The studies of Tau structure to date, have elucidated our understanding of Tau
structure both on and off the microtubule surface. However, many questions remain
including whether structural changes on the microtubule surface underlie Tau’s binding
behavior and ability to inhibit kinesin-1 motility. The work presented in this dissertation
represents a first attempt at linking Tau structural change to its behavior on the
microtubule surface and regulation of motor motility.
1.4 Purpose and Scope
One hundred and twelve years have passed since Santiago Ramón y Cajal gave his
acceptance speech in 1906. Over that time, the field has progressed in its understanding
of the neuron and the processes that ensure neuronal function. Despite the strides that
have been made, many questions remain open. One of the most basic and fascinating, is
the means by which cellular material manufactured in the cell body is moved throughout
the axon. This processes of axonal transport is a complex system of motors, microtubule
tracks and regulators that in the largest axon can stretch up to 2 meters (Britannica,
2018). During axonal development and throughout the life of the cell, Tau plays an
integral role in the regulation of this system (Figure 1.13). As described in the preceding
text, the signaling pathways that regulate axonal development and function converge on
the cytoskeletal elements involved in axonal transport. The regulation of axonal transport
is complex involving inter-play between the tracks, the motors and the microtubule
associated proteins. Of the microtubule associated proteins, Tau has been extensively
studied because of its involvement in transport regulation (Figure 1.13) throughout the
life of the cell and in disease development.
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Figure 1.13: Tau Functions in Axonal Transport
Tau has been shown to regulate axonal transport in a number of ways. A) Tau
isoforms differentially regulate microtubule growth and shortening (Panda et al.,
2003). B) Tau has also been shown to participate in signaling cascades. The PAD has
been shown to activate PP1 which in turn activates GSK3β. Activation of GSK3β,
leads to the phosphorylation of kinesin-1 light chains and the release of cargo (Morfini
et al., 2002; LaPointe et al., 2009). The PAD is shielded by tyrosine 18 (Y18)
phosphorylation (Kanaan et al., 2012). In the disease state, PAD shielding by Y18
phosphorylation prevents inhibition of axonal transport. C) Tau has been shown to
preferentially inhibit kinesin-1 motility in vitro (Dixit et al., 2008). This inhibition
does not disrupt cargo transport in vivo and raises the question of whether Tau is
regulated on the microtubule and how this regulation affects motor motility. The work
presented here focusses on cellular regulation of Tau’s structure and function by
phosphorylation and the role this may play in motor motility regulation.
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Since Tau was identified as a regulator of kinesin-1 motility (Heins et al., 1991),
efforts have been made to understand the means by which this regulation occurs and how
the cell controls this regulation (Ebneth et al., 1998; Trinczek et al., 1999; Seitz et al.,
2002). Counterintuitively, though Tau has been shown to inhibit kinesin-1 motility in
vitro in a concentration dependent manner (Dixit et al., 2008), cargo transport is not
inhibited by the high concentration of Tau (2-5 µM) found in the axon (Morfini et al.,
2007; Avila, 2010). This apparent disagreement between in vitro and in vivo observations
raises the question of how the cell regulates motor motility inhibition to allow for cargo
delivery in non-disease state conditions. In partial answer to this question, Tau has been
shown to bind the microtubule in a static-diffusive state equilibrium, which differs with
isoform and lattice, and corresponds with isoform ability to inhibit kinesin-1 motility
(Dixit et al., 2008; McVicker et al., 2011; Hinrichs et al., 2012; McVicker et al., 2014).
These studies do not explain the purpose of the static-diffusive state binding equilibrium
and do not show how this equilibrium is regulated. The work presented here aims to fill
this gap in our knowledge so that we can begin to understand how regulation of Tau’s
static-diffusive state equilibrium allows for cellular regulation of axonal transport.
In vitro work studying Tau microtubule binding behavior and motor motility
inhibition uses recombinant human Tau expressed in bacterial systems (Dixit et al., 2008;
McVicker et al., 2014). This method of expression does not allow Tau to be posttranslationally modified as it would be within the cell. Tau is subject to an incredible
number of post-translational modifications including 85 proposed or identified
phosphorylation events (Martin et al., 2013b). It is therefore not inconceivable that
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phosphorylation may play a role in the regulation of Tau function. In fact, it has been
shown that phosphorylation of tyrosine 18 prevents Tau disease state inhibition of axonal
transport (Kanaan et al., 2012). These results made tyrosine 18 an interesting target to
explore in the regulation of Tau behavior on the microtubule surface. In chapter two, we
address the question of how tyrosine 18 phosphorylation affects Tau’s ability to inhibit
kinesin-1 motility. We demonstrate that phospho-mimetics of tyrosine 18 in 3RS-Tau
exhibit a shift in static-diffusive state equilibrium towards the diffusive state, correlating
with a reduction in inhibition of kinesin-1 motility. We further demonstrate that the
static-diffusive state binding equilibrium is maintained ex vivo, as is the phosphorylation
mediated diffusive state shift. This work represents the first demonstration of a means by
which the cell can regulate Tau’s binding equilibrium. Furthermore, this is the first
evidence that Tau’s static-diffusive state equilibrium is maintained under physiological
conditions highlighting a role for static and diffusive binding in Tau’s cellular function.
While chapter 2 highlights the importance of regulating Tau’s binding equilibrium, it
also raises more questions about microtubule bound Tau. Tyrosine 18 phosphorylation is
an N-terminal modification. The N-terminal of Tau does not interact with the microtubule
surface (Goode et al., 2000), however, our results from chapter 2 demonstrate that
phosphorylation of tyrosine 18 affects Tau binding behavior. This indicates that tyrosine
18 phosphorylation potentially affects Tau binding through long range structural change.
Interestingly, in addition to regulating Tau’s static-diffusive state equilibrium, tyrosine 18
has been implicated in the stabilization of a solution based dynamic folded conformation
of Tau (Jeganathan et al., 2006).
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Admittedly, studying Tau’s conformation is challenging because it has no tertiary
structure (Cleveland et al., 1977). Solution based structural studies have shown that Tau
has a dynamic folded conformation (Jeganathan et al., 2006; Elbaum-Garfinkle and
Rhoades, 2012). However, these techniques have not been used to identify dynamic
structural changes on the microtubule surface. Cryo-EM studies have attempted to
visualize microtubule bound Tau and while they have had success resolving portions of
the protein, they cannot be used to study dynamic structural changes (Hirokawa et al.,
1988; Al-Bassam et al., 2002; Santarella et al., 2004; Kadavath et al., 2015; Kellogg et
al., 2018). The ‘fuzzy’ Tau coated microtubules that have been seen with cryo-EM do
however support the idea of dynamic structural change (Al-Bassam et al., 2002;
Santarella et al., 2004). Recent cryo-EM work has been able to show the interactions of
microtubules with microtubule binding repeats while Tau is bound statically (Kellogg et
al., 2018). These structures have higher resolution than previous work and confirm that in
the static state Tau binds along the protofilament with fully extended microtubule binding
repeats (Kellogg et al., 2018). While this study does not resolve Tau’s N- and C-termini
or the microtubule binding repeats in the diffusive state, it give us questions for future
study.
In chapter 3, we hypothesize that distinct structural changes underlie static versus
diffusive binding. Instead of solution or cyro-EM based studies, we use a three color
single molecule fluorescence resonance energy transfer assay imaging with total internal
reflection fluorescence microscopy and alternating laser excitation (ALEX) to show that
in the static state the N- and C- termini of Tau interact more closely than in the diffusive
state. Our assay allows us to observe dynamic structural changes while Tau is bound to
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the microtubule. The results indicate that there are indeed distinct structural changes that
underlie Tau’s binding equilibrium. Prior to this work, no studies have been done to
elucidate what structural changes underlie the static-diffusive binding equilibrium and
therefore Tau’s behavior and function on the microtubule surface.
Taken together, these studies demonstrate the link between structure and function of
Tau and the cellular means by which Tau behavior and function can be regulated. While
we have begun to address the link between Tau structure and function on the microtubule
surface, this work also points to new questions that must be answered. In chapter 4, I
outline our work in the context of the field and provide directions that the techniques we
have developed now allow us to take.
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CHAPTER 2: PHOSPHO-REGULATION OF TAU MODULATES KINESIN-1
MOTILITY
2.1 Abstract
Microtubule-based axonal transport is tightly regulated by numerous pathways
ensuring appropriate delivery of specific organelle cargoes to selected subcellular
domains. Highlighting the importance of this process, pathological evidence has linked
alterations in these pathways to the pathogenesis of several neurodegenerative diseases.
An important regulator of this system, the microtubule associated protein Tau has been
shown to participate in signaling cascades, modulate microtubule dynamics and
preferentially inhibit kinesin-1 motility. However the cellular means of regulating Tau’s
inhibition of kinesin-1 motility remains unknown. Tau is subject to various posttranslational modifications including phosphorylation, but whether phosphorylation
regulates Tau on the microtubule surface has not been addressed. It has been shown that
tyrosine 18 phosphorylated Tau regulates inhibition of axonal transport in the disease
state. Tyrosine 18 is both a disease and non-disease state modification and is therefore an
attractive starting point for understanding control of Tau’s inhibition of kinesin-1
motility. We show that pseudophosphorylation of tyrosine 18 reduces 3RS-Tau’s
inhibition of kinesin-1 motility. Additionally, we show that introduction of negative
charge at tyrosine 18 shifts Tau’s previously described static-dynamic state binding
equilibrium towards the dynamic state. We also present the first evidence of the
establishment of Tau’s static-dynamic state equilibrium under physiological conditions.

51

2.2 Introduction
The neuronal microtubule associated protein (MAP) Tau is involved in axonal
development from its earliest stages onwards (Andreadis, 2005). Tau has been implicated
in many processes within the neuron, the majority of which are associated with its
participation in axonal transport (AT). The AT system encompasses the microtubule
track, molecular motors including kinesin-1 and -2, numerous MAPs including Tau, and
many signaling cascades (Maday et al., 2014). Tau’s role in AT is multi-faceted, as it has
been shown to stabilize microtubules (Panda et al., 2003), participate in signaling
cascades (Kanaan et al., 2012) and inhibit kinesin-1 motility (Vershinin et al., 2007;
Dixit et al., 2008; McVicker et al., 2011). In the non-disease state Tau’s ability to
preferentially inhibit kinesin-1 motility is of particular interest when juxtaposed with the
failure of this inhibition to disrupt normal cargo delivery, suggesting that Tau has a role
in the modulation of kinesin-mediated cargo delivery during AT (Kanaan et al., 2012).
This highlights the importance of cellular regulation of Tau’s inhibitory function of
kinesin-1 transport during AT, but how this control is achieved is currently unknown.
Understanding Tau’s function and corresponding regulation is compounded by its
sequence diversity. There are six Tau isoforms which arise from strict developmental
regulation of the alternative splicing of the MAPT gene on chromosome 17 (Andreadis,
2005; Ballatore et al., 2007). While all six isoforms have a central proline rich region
(PRR) and N-terminal phosphatase activating domain (PAD) (Ballatore et al., 2007;
Kanaan et al., 2012), they differ by number of C-terminal microtubule binding repeats
(three – four) and N-terminal acidic inserts (zero – two) (Goode et al., 2000; Ballatore et
al., 2007). Tau’s role in signaling is partly mediated by its PAD which has been shown to
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activate protein phosphatase 1 (PP1) (LaPointe et al., 2009; Kanaan et al., 2011). In the
disease state, a phospho-mimetic of tyrosine 18 (Y18), the last residue in the PAD, has
been shown to prevent the inhibition of axonal transport when incorporated into
neurofibrillary tangles (Kanaan et al., 2012). Y18 is predominantly phosphorylated by the
Src family kinase Fyn in both the disease and non-disease states (Lee et al., 1998;
Kanaan et al., 2012; Larson et al., 2012).
Adding to this isoform diversity, it has recently been shown that Tau can bind the
microtubule in an equilibrium between static and ATP-independent dynamic states
(Vershinin et al., 2007; Dixit et al., 2008; Hinrichs et al., 2012). We have shown that the
static-dynamic state equilibrium differs with Tau isoform and microtubule lattice
structure with the shortest isoform, 3RS-Tau, being more static on paclitaxel stabilized
microtubules than the longest isoform, 4RL-Tau (McVicker et al., 2014). Tau’s ability to
inhibit kinesin-1 motility also differs with isoform. 3RS-Tau, which favors the static
state, is more inhibitory to kinesin-1 than 4RL-Tau (Dixit et al., 2008; McVicker et al.,
2011). This correlation indicates that the static state is more inhibitory to kinesin-1
motility than the dynamic state. Given these isoform-specific differences in behavior, a
common mechanism for regulating multiple Tau isoforms and their static-dynamic state
equilibria remains unclear.
All isoforms of Tau are subject to a variety of post-translational modifications
(Watanabe et al., 1993; Funk et al., 2014; Kamah et al., 2014) which may have important
roles in many aspects of Tau regulation. We postulate that post-translational
modifications (especially phosphorylation) are the link between controlling Tau’s staticdynamic equilibrium and Tau’s inhibition of kinesin-1 motility. As stated above, static
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Tau is more inhibitory to kinesin-1 motility than dynamic Tau (McVicker et al., 2011)
while phosphorylation/a phospho-mimetic of Y18 has been shown to prevent inhibition
of axonal transport in the disease state (Kanaan et al., 2012). We hypothesize that the
negative charge provided by phosphorylation of Y18 stabilizes the dynamic
state/destabilizes the static state thereby shifting the static-dynamic equilibrium towards
the less inhibitory dynamic state. To test this hypothesis, we generated phospho-mimetic
and control 3RS-Tau constructs by mutating Y18 to glutamic acid (Y18E 3RS-Tau) and
alanine (Y18A 3RS-Tau). To study the effect of increasing the negative charge at/around
Y18, a double phospho-mimetic was generated by mutating threonine 17 and Y18 to
glutamic acid (dE 3RS-Tau). Using total internal reflection fluorescence (TIRF)
microscopy, we observed single molecule 3RS-Tau interactions with paclitaxel stabilized
microtubules. Our results provide the first evidence for direct control by phosphorylation
of Tau’s dynamic behavior, and therefore its function, on the microtubule surface.
2.3 Results
Introduction of negative charge at Y18 reduces 3RS-Tau inhibition of kinesin-1 motility.
TIRF microscopy was used to visualize kinesin-1 motility (Figure 2.1) on paclitaxel
stabilized microtubules in the presence of 200 nM unlabeled and Alexa 488 labeled WT
and Y18E 3RS-Tau (1:5; Tau:tubulin) (Figure 2.2A). In the absence of Tau, kinesin-1
had a run length of 1.64

0.50 µm (Figure 2.2B) which was significantly decreased in

the presence of both unlabeled and labeled WT 3RS-Tau (0.99

0.23 µm and 0.99

0.24 µm; Figure 2.2, C and D; Supplemental Table S2.2; Supplemental Figure S2.1) as
we have previously demonstrated (McVicker et al., 2011). Interestingly however,
kinesin-1’s run length significantly increased in the presence of Y18E 3RS-Tau
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(unlabeled = 1.37

0.39 µm, labeled = 1.35

0.39 µm; Figure 2.2, E and F) compared

to the WT 3RS-Tau condition (Figure 2.2, C and D). Kinesin-1’s velocity did not differ
under any of the conditions tested (Supplemental Table S2). These results indicate that
introduction of negative charge at Y18 reduces 3RS-Tau’s inhibition of kinesin-1 run
length without affecting its velocity. WT Tau’s ability to inhibit kinesin-1 run length
without affecting velocity has been reported previously (Dixit et al., 2008). This is the
first evidence for phosphorylation mediated regulation of 3RS-Tau’s ability to inhibit
kinesin-1 motility.
A Y18 phospho-mimetic of 3RS-Tau exhibits a significant shift towards the dynamic state
in vitro. Given the results of our motility assays, we wanted to know if the introduction of
negative charge at Y18 affects Tau’s static-dynamic equilibrium on the microtubule
surface. TIRF microscopy was used to visualize the interactions of the constructs used in
the motility assays (WT and Y18E 3RS-Tau) (Figure 2.3A) with TRITC rhodamine
labeled paclitaxel stabilized microtubules at 200 nM Tau (1:5, Tau:tubulin). We observed
predominantly static events for WT 3RS-Tau (77.1 ± 4.2 %, Figure 2.3B; Supplemental
Table S2.3), a result which we have previously demonstrated (McVicker et al., 2014).
Conversely, we observed a significant decrease (p < 0.05) in the number of static events
for Y18E 3RS-Tau (47.7 ± 5.0 %, Figure 2.3B; Supplemental Table S2.3).
Static dwell times for WT 3RS-Tau were best fit to a two phase exponential function.
This revealed one population of long dwell times and one of short dwell times
(Supplemental Figures S2.2A and S2.3; Supplemental Table S2.3), most likely
corresponding to the small multi-protein complexes (long dwell times) and single
molecule interactions (short dwell times) with the microtubule surface that we have
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previously observed in the static state (McVicker et al., 2014). Y18E 3RS-Tau static
dwell times were best fit to a one phase exponential function (Supplemental Figure S2.2B
and S2.3; Supplemental Table S2.3) with an average of 14.5 s which is comparable to
WT 3RS-Tau’s long static dwell time of 15.7 s. Dynamic dwell times for both WT and
Y18E 3RS-Tau were best fit to one phase exponential functions (Supplemental Figure
S2.2C and D; Supplemental Figure S2.3; Supplemental Table S2.3) and did not differ
from each other. The ability to control the equilibrium between the static and dynamic
states of Tau, and to specifically regulate that control by mimicking phosphorylation at
Y18, has not been previously demonstrated.
Phospho-mimetic constructs of Y18 3RS-Tau bind with decreased affinity for the
microtubule. Given the observed shift towards the dynamic state we considered the
possibility that the introduction of negative charge at Y18 reduced Tau’s affinity for the
microtubule surface. This would also lead to a decrease in 3RS-Tau’s ability to inhibit
kinesin-1 motility. To address this, TIRF microscopy was used to image increasing
concentrations (50-650 nM) of Alexa 532 labeled 3RS-Tau binding to HiLyte 488
labeled, paclitaxel stabilized microtubules (Figure 2.4A). An unphosphorylatable
construct (Y18A 3RS-Tau) and a construct with increased negative charge (dE 3RS-Tau)
were observed alongside WT and Y18E 3RS-Tau in an effort to better understand the
effect of the introduction of negative charge. The average intensity of Alexa 532 labeled
3RS-Tau per unit length along the microtubule was measured and plotted against Tau
concentration. The plots were then fit to one site-specific binding curves from which the
KD was determined. We found that WT 3RS-Tau binds the microtubule with a KD of 150
± 126 nM while Y18A 3RS-Tau had a KD of 331 ± 100 nM (Figure 2.4B; Supplemental
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Table S2.3). Introduction of increasing negative charge decreased the affinity of Tau for
the microtubule as evidenced by a KD of 700 ± 318 nM for Y18E 3RS-Tau with an even
greater decrease for dE 3RS-Tau (

of 902 ± 266 nM) (Figure 2.4B; Supplemental

Table S3).
Phospho-mimetic mediated shift towards the dynamic state is maintained for comparable
bound fractions of 3RS-Tau. Using the KD values from our binding assays, we determined
that at a microtubule concentration of 1 uM, WT 3RS-Tau had a bound fraction of 87%
while Y18E 3RS-Tau’s bound fraction was 59%. At the high concentration used in our
kinesin-1 motility assays (200 nM; 1:5 (Tau:tubulin)), WT 3RS-Tau would have a
microtubule bound concentration of 174 nM while Y18E 3RS-Tau would have 118 nM
bound. The inhibition of kinesin-1 by Y18E 3RS-Tau that we observed for this high
concentration could then be attributed to this difference in bound fraction of Tau. To
address this possibility, we observed WT, control (Y18A) and phospho-mimetic (Y18E,
dE) constructs of 3RS-Tau at 10 nM (1:3000; Tau:tubulin) where the bound
concentrations of WT (9 nM), Y18A (7 nM), Y18E (7 nM) and dE (5 nM) 3RS-Tau were
comparable. At this concentration, the percentage of static events for Y18A (77.8 ±
4.2%) was not significantly different from WT 3RS-Tau (81.4 ± 3.9%) (Figure 2.5;
Supplemental Table S2.3). Under these conditions Y18E 3RS-Tau had a static population
of 67.4 ± 4.7% (Figure 2.5; Supplemental Table S2.3) which was a statistically
significant difference from WT 3RS-Tau (p < 0.05) and Y18A 3RS-Tau (p < 0.05)
(Figure 2.5; Supplemental Table S2.3). dE 3RS-Tau had a static population of 51.4 ±
5.0% (Figure 2.5; Supplemental Table S2.3) which was a statistically significant decrease
compared to Y18E 3RS-Tau (p < 0.05).
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Dynamic state dwell times for WT, Y18A, Y18E and dE 3RS-Tau (Supplemental Figure
S2.4, A-D; Supplemental Table S2.3), were best fit to one phase exponential functions
and did not significantly differ. Dwell times for static events from WT, Y18A, Y18E and
dE 3RS-Tau populations were best fit to two phase exponential functions (Supplemental
Figure S2.5, A-D). Though there was a slight decrease in the long and short dwell times
for Y18E 3RS-Tau (Supplemental Figure S2.5C; Supplemental Table S2.3) and an
increase in the short dwell time for dE 3RS-Tau (Supplemental Figure S2.5D;
Supplemental Table S2.3); the WT, Y18A and dE 3RS-Tau dwell times (long) were not
appreciably different. This result indicates that the observed shift towards the dynamic
state is independent of the fraction of Tau bound to the microtubule.
Negative charge mediated shift towards the dynamic state is maintained ex vivo. All the
in vitro assays presented here were performed at low ionic strength. We therefore asked if
the effect of negative charge on 3RS-Tau’s behavior was still present under more
physiologically relevant conditions. TIRF microscopy was used to visualize Tau behavior
(Figure 2.6) in ex vivo preparations of axoplasm extruded from the giant axons of
Atlantic squid (Loligo pealei). The extruded axoplasm samples were perfused with a
mixture of Alexa 568 labeled WT, Y18A or Y18E 3RS-Tau to visualize microtubules and
Alexa 488 labeled WT, Y18A or Y18E 3RS-Tau to observe single molecule events
(Supplemental Movie S2.4 and S2.5). Non-phosphorylatable Y18A 3RS-Tau had a static
population of 82.0 ± 3.8 % (Figure 2.7; Supplemental Table S2.3). This was statistically
significant from static populations for WT (74.0 ± 4.4 %) and Y18E 3RS-Tau (73.2 ± 4.4
%) (p < 0.05) (Figure 2.7; Supplemental Table S2.3). These results highlight the
importance of using an unphosphorylatable construct to prevent possible ex vivo
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phosphorylation at Y18. Based on this data we conclude that the Y18E mediated shift
towards the dynamic state observed in vitro is maintained within the axoplasm. Unlike
the in vitro dwell times, all ex vivo dwell times for WT, Y18A and Y18E 3RS-Tau best
fit a single exponential function. There was no difference in the ex vivo static dwell times
(Supplemental Figure S2.6, A-F; Supplemental Table S2.3) for WT, Y18A and Y18E
3RS-Tau. We observed ex vivo dwell times which were an order of magnitude shorter
than the in vitro dwell times (Supplemental Figures S2.2, S2.4 and S2.5). This difference
has been previously observed (Janning et al., 2014) and can most likely be attributed to
the increased ionic strength found under physiological conditions. This is the first
evidence demonstrating that the static-dynamic equilibrium of Tau on the microtubule
surface observed in vitro is present under conditions found within the axon.
2.4 Discussion
Recently, we have shown that Tau’s established ability to inhibit kinesin-1
motility differs with isoform (McVicker et al., 2014). However, the cellular means of
regulating Tau’s inhibition of kinesin-1 is still not understood. Y18 phosphorylation is of
particular interest because of its role in preventing the inhibition of axonal transport in the
disease state (Kanaan et al., 2012) and its possible involvement in stabilizing a nondisease state dynamic folded conformation of Tau in solution (Jeganathan et al., 2006).
Our results (Figure 2.2) are the first evidence of phosphorylation regulating Tau’s ability
to inhibit kinesin-1.
We hypothesized two possible explanations for the reduced inhibition of kinesin1. Introduction of negative charge at Y18 could shift the static-dynamic state equilibrium
towards the less inhibitory dynamic state. Alternatively, the negative charge at Y18 could
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decrease Tau’s affinity for the microtubule surface, effectively reducing the number of
Tau obstacles for kinesin-1 to circumnavigate. Specifically for our kinesin-1 motility
assay conditions (1:5, Tau:tubulin) (Figure 2.2), a final concentration of 200 nM Tau was
used for which WT 3RS-Tau had a fraction bound of 87% (174 nM) compared to Y18E
3RS-Tau’s fraction bound of 59% (118 nM) (based on binding assay results; Figure 2.4).
But we also found that Y18E 3RS-Tau’s shift towards the dynamic state is maintained at
comparable fractions of Tau bound to the microtubule surface (5-9 nM) (Figure 2.5).
Therefore, the dynamic state shift observed upon Y18 phosphorylation is intrinsic to
behavior of individual Tau molecules and not dependent on amount of Tau bound to the
microtubule.
However, the difference in affinity for the microtubule between WT and Y18E
3RS-Tau must still be taken into account. Though the exact structural changes that
underlie static vs dynamic binding are not well understood, the negative charge mediated
decrease in affinity indicates that long range structural interactions may affect protein
binding and behavior. Based on the behavior observed in the high concentration
dynamics assays (Figure 2.3), 134 nM of the bound WT 3RS-Tau would be static while
for Y18E 3RS-Tau 56 nM would be static. For 1 µM of microtubules, statically bound
WT 3RS-Tau would occupy 13% of the available kinesin-1 binding sites while static
Y18E 3RS-Tau would occupy 5% of the available binding sites. This indicates that Y18E
3RS-Tau’s decreased inhibition of kinesin-1 is due to a combination of a decreased
bound fraction and an equilibrium shift towards the dynamic state. Ultimately this leads
to a reduction in the number of static Tau obstacles that kinesin-1 encounters on the
microtubule surface.
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It has previously been demonstrated that with increasing concentration Tau forms
multi-protein patches on the microtubule surface (Dixit et al., 2008). Our high
concentration behavioral assays (Figure 2.3, Supplemental Table S2.3) show two
populations of WT 3RS-Tau static dwell times. The long dwell time (Supplemental Table
S2.3, Supplemental Figures S2.2 and S2.3) may be indicative of multi-protein complexes
formed by N-terminal region mediated Tau-Tau interactions (Feinstein et al., 2016). The
loss of a short static dwell time for Y18E 3RS-Tau (Supplemental Table S2.3,
Supplemental Figure S2.2) indicates that with the introduction of negative charge at high
concentration, static binding may only occur when multi-protein complexes are formed.
Additionally, the introduction of N-terminal negative charge may disrupt complex
formation (Feinstein et al., 2016) which would lead to the observed shift towards
dynamic binding at high concentration (Supplemental Table S2.3). In keeping with these
results we have previously shown that 4RL-Tau which has two acidic N-terminal inserts,
forms smaller multi-protein complexes and is more shifted towards dynamic binding than
3RS-Tau which has no acidic inserts (McVicker et al., 2014). At low concentration
(Figure 2.3), static binding is not governed by concentration driven complex formation.
Tau’s inhibition of kinesin-1 motility does not impact velocity (Supplemental
Table S2.2) (Dixit et al., 2008). We have previously demonstrated that while kinesin-1
pauses both in the presence and absence of Tau the pause-step frequency does not change
(Hoeprich et al., 2014). Therefore, the effect of pausing on velocity is not significant. An
increase in run termination would lead to the observed decrease in run length.
We have previously reported the importance of the lattice structure in regulation
of Tau isoforms’ static-dynamic state equilibria (McVicker et al., 2014). Tau’s ability to
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inhibit kinesin-1 motility is also regulated by lattice structure (McVicker et al., 2011). On
GMPCPP stabilized microtubules, 3RS-Tau binds dynamically and does not inhibit
kinesin-1 motility (McVicker et al., 2011; McVicker et al., 2014). Tau’s inhibitory effect
is restored on paclitaxel stabilized microtubules where 3RS-Tau’s binding equilibrium is
shifted towards the static state (McVicker et al., 2011; McVicker et al., 2014). The
present study demonstrates that lattice regulation is not the only means available for
control of Tau’s binding equilibrium. Controlling Tau’s intrinsic equilibrium through
phosphorylation and the microtubule lattice structure through nucleotide binding states
and PTMs (McVicker et al., 2014; Yu et al., 2015) gives the cell greater flexibility in
regulating Tau obstacles and allows for continued AT. We have demonstrated that Tau’s
static-dynamic state equilibrium is maintained under physiological conditions and that the
shift towards the dynamic state that we observed in vitro occurs ex vivo (Figure 2.5). As
we have shown and has been previously reported (Janning et al., 2014), Tau binds both
dynamically and transiently to the microtubule surface under physiological conditions.
Extending this observation, we emphasize the importance of regulating these dynamic
interactions to control Tau function. It should be noted that the dwell times reported here
are longer than those previously reported (Janning et al., 2014), which may relate to the
different Tau constructs and neuronal systems used, and highlight the importance of
further study to better understand Tau dynamics in vivo.
Within the axon phosphorylation of Y18, the last residue of the PAD, not only
shields the PAD (Kanaan et al., 2012), but as our results show, the negative charge
provided by phosphorylation facilitates a dynamic state shift independent of fraction
bound (Figures 2.3 and 2.5). This gives the cell two levels of regulating Tau’s function by
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preventing Tau signaling through the PAD and Tau’s physical inhibition of kinesin-1
motility. In this model while Y18 is phosphorylated, individual motors continue to
transport cargo (Figure 2.8). Dephosphorylation of Y18 leads to signaling activation
(Kanaan et al., 2012) and increased physical inhibition of kinesin-1 motility (Figure 2.8).
Exposure of Tau’s PAD has been shown to ultimately activate glycogen synthase kinase
3β (GSK-3β) which in addition to phosphorylating Tau (Lovestone et al., 1996; Martin et
al., 2013b) can phosphorylate kinesin light chains (Morfini et al., 2002) (Figure 2.8).
This leads to further disruption of cargo-motor interactions leading to the dissociation of
motors from cargo, thereby allowing cargo delivery (Morfini et al., 2002) (Figure 2.8).
PAD shielding by phosphorylation of Y18 (Kanaan et al., 2012) may partly
depend on structural change. The misregulation of Tau’s structure (Elbaum-Garfinkle and
Rhoades, 2012) and therefore its function could be a common pathway by which
neurodegeneration occurs in diseases where shifts in isoform expression and aberrant
phosphorylation lead to the same outcome (Qian et al., 2013; Gerson et al., 2014).
Control of Tau’s function is further complicated by abnormal modifications which
occur in the disease state (Morris et al., 2015). Our group and others have previously
shown that Tau’s ability to inhibit kinesin-1 motility differs with isoform (Vershinin et
al., 2007; Dixit et al., 2008; McVicker et al., 2011) as does the static-dynamic state
equilibrium (McVicker et al., 2014). The results we present here indicate that
phosphorylation provides a common means of regulating the isoforms and their
equilibria. Perturbing the equilibrium between the static and dynamic states would lead to
disruption of cargo transport within the axon by disrupting inhibition of kinesin-1
motility and release of cargo. Given our results, it is highly likely that the equilibrium

63

between the static and dynamic states is spatially regulated in order to effectively control
local cargo delivery. This localized signaling would require the involvement of multiple
signaling pathways and a complex pattern of Tau phosphorylation. To date, it is not
known how these phosphorylation events affect the normal behavior of the protein or
how the cell balances N- and C-terminal phosphorylation to maintain a working staticdynamic state equilibrium. In addition to phosphorylation, Tau is subject to acetylation
(Kamah et al., 2014) and methylation (Funk et al., 2014), whose purposes in the
regulation of Tau’s function have yet to be fully understood. It is imperative that the
balance of non-disease state modifications, especially phosphorylation, is understood
given that one of the first steps in neurodegeneration may be disruption of these normal
modifications. We have begun to elucidate the importance of regulating phosphorylation
at specific sites to control Tau function. Here we have highlighted new implications for
the cellular control of Tau’s static-dynamic state equilibrium in axonal transport under
both normal and disease state conditions.
2.5 Materials and Methods
All protein work and experiments were done in BRB80 (80 mM PIPES, 1 mM
EGTA, 1 mM MgCl2, pH 6.9 at room temperature) unless otherwise noted.
Tau Mutant Generation, Purification and Labeling Alanine/glutamic acid 3RS-Tau
constructs were generated using the QuikChange II XL Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA). Constructs were then expressed in BL21CodonPlus(DE3)-RP Escherichia coli cells (Stratagene, La Jolla, CA) and purified using
Q and SP Sepharose (Sigma-Aldrich, St. Lois, MO) affinity column chromatography
(McVicker et al., 2011; McVicker et al., 2014). Following purification, samples were
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dialyzed against BRB80 and protein concentrations were determined with the bicinchonic
acid (BCA) assay (Pierce, Rockford, IL) using WT 3RS-Tau standards. The
concentrations were then validated with SDS PAGE gels (Bio-Rad, Hercules, CA). For
labeling, samples were incubated with 10-fold molar excess Dithiothreitol (DTT) at room
temperature for 2 h followed by DTT removal with a 2 ml 7K MWCO ZebaTM spin
desalting column (Peirce, Rockford, IL). Samples were then incubated with 3-fold molar
excess of Alexa Fluor® (488, 532 or 568) C5 Maleimide (Invitrogen Molecular Probes,
Carlsbad, CA) for 2 h at room temperature. Excess fluor was removed with desalting
columns. A 640® Spectrophotometer (Beckman, Pasadena, CA) was used to determine
the labeling efficiency using the following Alexa extinction coefficients: Alexa 488 –
71,000 cm-1M-1 at 495 nm; Alexa 532 – 78,000 cm-1M-1 at 532 nm; Alexa 568 – 88,000
cm-1M-1 at 578 nm. The protein concentration was determined using the BCA assay and
the ratio of fluor concentration to protein concentration was calculated. All Tau proteins
had labeling efficiencies of 30 - 86% (detailed in Supplemental Table S2.1).
Tubulin Purification and Microtubule Preparation Tubulin was purified from bovine
brain obtained from Vermont Livestock & Slaughter (Ferrisburgh, VT) as previously
described (McVicker et al., 2014). Purified tubulin was clarified by ultracentrifugation
(20 min, 95,000 rpm, 4oC) in an OptimaTM TLX Ultracentrifuge (Beckman, Pasadena,
CA). Following clarification, tubulin was mixed with rhodamine-labeled tubulin
(Cytoskeleton Inc., Denver, CO) at a 1:200 (labeled:unlabeled) ratio and supplemented
with 1 mM GTP (Sigma-Aldrich, St. Lois, MO). This mixture was incubated for 20 min
at 37oC. Following polymerization, microtubules were stabilized with 20 µM paclitaxel
(Sigma-Aldrich, St. Lois, MO). Post-clarification tubulin concentration was calculated
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with the spectrophotometer using the tubulin extinction coefficient of 115,000 cm-1M-1 at
280 nm.
Coverslip Preparation and Flow Chamber Assembly For silanization, glass coverslips
were incubated in 100% methanol for 2 h with shaking. Methanol-washed coverslips
were then plasma cleaned (Harrick Plasma Cleaner, HarrickPlasma, Ithaca, NY) for 2-5
min and then incubated in a silane mixture (97% toluene (Sigma-Aldrich, St. Lois, MO),
2% 2-methoxy(polyethyleneoxy)propyltrimethoxysilane (Gelest Inc., Morrisville, PA),
and 1% butylamine (Acros Organics, New Jersey, USA)) with flowing nitrogen gas for
90 min (Lowndes and Nelson, 2013). Coverslips were then washed in toluene (Lowndes
and Nelson, 2013) and then dried and cured with flowing nitrogen gas for 30 min. Using
Norland optical adhesive (Norland Products, Cranbury, NJ), flow chambers were
constructed by adhering ARTUS shims (ARTUS, Eaglewood, NJ) to the silanized glass
coverslips before 15 min UV irradiation (McVicker et al., 2011).
In vitro TIRF Dynamics Assay Paclitaxel stabilized microtubules were incubated with
WT, alanine (Y18A), single glutamic acid (Y18E) or double glutamic acid (dE) 3RS-Tau
constructs at a 1:3000 (Tau:tubulin) ratio (10-12 nM) 30 min prior to imaging. For
imaging, washes and incubations were performed with BRB80+OS (BRB80
supplemented with a previously published oxygen scavenging system (McVicker et al.,
2011)). Flow chambers were incubated with monoclonal anti-β III (neuronal) tubulin
antibodies (Sigma-Aldrich, St. Lois, MO) at 33 µg/mL for 5 min followed by a 5 min 2X
chamber volume wash with 2mg/mL BSA (Sigma-Aldrich, St. Lois, MO). Alternatively,
a 5 min 2.5% Pluronic® F-127 (Sigma-Aldrich, St. Lois, MO) incubation was done before
the chambers were washed (10X chamber volume) with BSA for 5 min to remove excess
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Pluronic® F-127. Chambers were then incubated for 12 min with microtubule/Tau
mixtures diluted to 0.5-1 µM. Finally, chambers were washed with 160-333 pM Tau
(1:3000 imaging concentration) for 2-4 min to remove non-adherent microtubules. All
Tau and microtubule dilutions were made in warm (37oC) BRB80+OS.
To observe Tau’s behavior at a 1:5 (Tau:tubulin) ratio, the needed concentration
of unlabeled WT or Y18E 3RS-Tau (200 nM) was spiked with 500 pM Alexa 488 labeled
WT or Y18E 3RS-Tau. Microtubules were stabilized as described above and were
incubated with either the WT or Y18E 3RS-Tau spike mixture 30 mins prior to imaging.
As before, washes and incubations were performed with warm BRB80+OS.
Microtubule/Tau mixtures were diluted to a final imaging concentration of 1 µM.
Chambers were prepared as previously detailed and were then incubated with diluted
microtubule/Tau mixtures. Chambers were washed with warm WT or Y18E 3RS-Tau
mixtures (see above for concentrations) to remove non-adherent microtubules and keep
Tau concentrations constant (2-4 min).
An inverted Eclipse Ti-U Microscope (Nikon, Melville, NY) with a 100X
PlanApo objective lens (1.49 NA) and auxiliary 1.5X magnification and an XR/Turbo-Z
(Stanford Photonics, Palo Alto, CA) camera running Piper Control v2.3.39 or v2.6.09
(Stanford Photonics, Palo Alto, CA) was used to perform TIRF microscopy as previously
described (Previs et al., 2012; Hoeprich et al., 2014; Previs et al., 2015). Alexa 488
labeled Tau and rhodamine labeled tubulin were excited and imaged as previously
described with 473 nm or 532 nm argon lasers and previously reported emission filters
(McVicker et al., 2014). Images were collected at room temperature at 10 frames/s, 95 or
93 nm/pixel, 50 frames for microtubules and 500 or 1000 frames for Tau.
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TIRF Binding Assay The affinity and cooperativity of 3RS-Tau binding to microtubules
were assessed using a TIRF-based binding assay. Microtubules were prepared as
described above expect that labeling was carried out with porcine HiLyte 488 labeled
tubulin (Cytoskeleton Inc., Denver, CO) at a 1:400 (labeled:unlabeled) ratio. Tau
constructs were labeled with Alexa 532 as described above. As with the in vitro
Dynamics Assay, all dilutions, washes and incubations were done in BRB80+OS. Final
Tau and microtubule dilutions were done in warm BRB80+OS as described above.
Microtubules were polymerized as described except that no Tau was added prior to
imaging. Microtubules were then flowed into prepared flow chambers at 1.5 µM as
described above. Initially, chambers were washed to remove non-adherent microtubules.
Then, 50 nM Tau was flowed in and imaged. Following this, increasing concentrations
of Tau were flowed in and imaged until a final concentration of 650 nM was reached. 20
frames of Tau were collected at 10 frames/s for each concentration. Imaging was done on
the same system with the same conditions used for the in vitro TIRF Dynamics Assay
described above.
Ex vivo TIRF Dynamics Assay To visualize Tau under physiological conditions,
Atlantic squid (Loligo pealii; Marine Biological Laboratory in Woods Hole, MA) axons
were isolated and their axoplasms extruded following previously established protocols
(Brady et al., 1993; Song and Brady, 2013). Briefly, flow chambers were constructed
using 25 x 75 x 1 mm glass slides (VWR Scientific, Radnor, PA) and strips of 22
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mm coverslips (VWR Scientific, Radnor, PA) cut with a diamond tipped pen and coated
with Compound III Silicon grease (Dow Corning, Midland, MI). Paired axoplasms were
extruded onto individual chamber slides. Flow chambers were then completed by adding
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a top coverslip that was silanized as previously described. Chambers were then secured
with a 1:1:1 lanoline, vaseline and paraffin mixture (Song and Brady, 2013).
Tau constructs were initially diluted in 20 mM HEPES (pH 7.2) and all axoplasm
imaging was done in Buffer X/0.8 (437.5 mM potassium aspartate, 162.5 mM taurine,
87.5 mM betaine, 62.5 mM glycine, 25 mM HEPES, 16.25 mM MgCl2, 12.5 mM EGTA,
3.75 mM CaCl2, 1.25 mM glucose, pH 7) (Song and Brady, 2013) diluted to Buffer X/2
with ddH2O. Perfusion mixtures were made with 200 nM Alexa 568 labeled Y18A or
Y18E 3RS-Tau, 500 pM Alexa 488 labeled Y18A or Y18E 3RS-Tau and a final ATP
concentration of 1 mM. Following perfusion, axoplasms were incubated at room temp for
20 min before imaging began. An inverted Eclipse Ti microscope (Nikon, Melville, NY)
with a 100x Apochromatic objective lens (1.49 NA) was used to carry out TIRF
microscopy with 488 nm (LU-NV laser combiner, Nikon, Melville, NY) and 561 nm
(Agilent MLC400 Monolithic Laser Combiner, Santa Clara, CA) lasers and emission
band-pass filter sets 525/50 nm and 600/50 nm (Chroma Technology, Bellows Falls, VT).
An Andor iXon Ultra 897 camera (Belfast BT12 7AL, UK) running NIS-Elements AR
v4.30.02 (Nikon, Melville, NY) was used to image Tau in the axoplasm. The relatively
high concentration of Alexa 568 (200 nM) labeled Tau allowed for visualization of
microtubules while the low Alexa 488 (500 pM) labeled Tau concentration allowed
imaging of single Tau molecules. One hundred frames each were collected at room
temperature of microtubules and Tau with an interval of 0.3 s and a pixel size of 0.16 x
0.16 µm.

In vitro Kinesin-1 Motility Assay Motility assays were performed with a truncated (560
aa) Drosophila melanogaster biotin tagged kinesin-1 construct (gift from Hancock lab).
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Motors were labeled with streptavidin conjugated Qdot® 655 (Life Technologies,
Carlsbad, CA) at a 1:4 (motor:Qdot) ratio. Paclitaxel stabilized microtubules were
prepared as described above except that after polymerization microtubules were
centrifuged at room temperature for 30 min before the pellet was resuspended in motility
assay buffer (MAB) (10 mM PIPES, pH 7.4 at room temperature, 50 mM potassium
acetate, 4 mM magnesium acetate, 1 mM EGTA) at 37oC supplemented with an oxygen
scavenging system (MAB+OS) as previously described (Hoeprich et al., 2014). Prior to
imaging, microtubules were incubated with Tau (Alexa 488 labeled or unlabeled WT or
Y18E 3RS-Tau) at a 1:5 (Tau:tubulin) ratio for 20 min at 37oC. Flow chambers were
prepared by incubation with monoclonal anti-tubulin antibodies (detailed above) diluted
with MAB+OS. Blocking and washing were done as previously detailed. Briefly,
chambers were blocked with 0.5 mg/mL of BSA in MAB+OS before 1 μM of
microtubules or microtubules/Tau as added and incubated as for the Tau behavioral
assays. Non-adherent microtubules were removed with an MAB+OS wash. A working
concentration of 20 pM – 50 pM kinesin-1 along with 1 mM ATP was added just prior to
imaging. Imaging was performed on the same system as the in vitro Tau assays. Qdots
were excited with the 473 nm laser and all movies were acquired at five frames per
second.

Data Analysis In vitro TIRF Dynamics Assays ImageJ 1.48v (NIH, Bethesda, MD) was
used to create kymographs of Tau interacting with the microtubule using the
MultipleKymograph plugin. To determine dwell times, the MTrackJ plugin was used to
measure the length of events that were clearly static or dynamic. Eleven percent of events
display switching and were not included in further analysis. Only events that began,
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remained and ended on the microtubule during the imaging period were used. Dynamic
and static dwell times were exported to GraphPad Prism v6.00 (GraphPad Software, La
Jolla, CA). Cumulative frequency distribution plots were generated for each population
and fit to one or two phase exponential functions. Average dwell times were calculated as
the time constant of the exponential function. The goodness of the fit (R2) and the 95%
confidence bands were also reported.

Fisher’s Exact Test was used to determine

statistical significance for static compared to dynamic populations of 3RS-Tau construct
data sets. All data sets are composites of data collected on different days. High
concentration (Spike): (WT, N = 8; Y18E, N = 8), comparable bound fraction: (WT, N =
12; Y18A, N= 5; Y18E, N = 4; dE, N = 5).
Ex vivo TIRF Dynamics Assay Events were tracked using the MTrackJ plugin for ImageJ.
Events were chosen if they lasted more than one frame and if the signal remained within
a snap range of 13 x 13 pixels from one frame to the next (snap range chosen based on
maximum diffusive range of a Tau protein (Konzack et al., 2007)). Tracks were exported
to Excel and events with a max distance from start
events

0.5 µm were designated static while

0.5 µm were designated dynamic. GraphPad Prism was used as described

above, to plot the cumulative frequency distribution of the dwell times to which one
phase exponential functions were fit. The average dwell time was determined from the fit
of the exponential function. As above, the goodness of the fit (R2) and the 95%
confidence bands were reported. Statistical significance was determined using Chi-square
with Yates’ correction. All data sets are comprised of data collected on different days
(WT, N = 4; Y18A, N= 5; Y18E, N = 5).
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TIRF Binding Assay The average intensity (Avg I; Arbitrary Units) per unit length of Tau
binding the microtubule was measured for each frame using the Multi Measure plugin for
ImageJ. In GraphPad Prism, the average AvgI per unit length was used to plot
vs [Tau]. Binding curves were fit to one site-specific binding with Hill
slope, which was used to determine the Hill coefficient and KD using the Hill equation:

where h is the Hill coefficient and Amax is the maximum

The

reported here was normalized to Amax. Tau’s fraction bound (fB) for the kinesin-1
motility assay was determined using the equation:

where [MT] is the concentration of microtubules used for imaging and

is the

affinity of Tau for the microtubule surface calculated in the binding assay. All data sets
are comprised of data collected on different days (WT, N = 4; Y18A, N= 3; Y18E, N =
3).
In vitro Kinesin-1 Motility Assay Data were analyzed as reported previously (Hoeprich et
al., 2014). Briefly, the MTrackJ plugin for ImageJ was used to measure motility while the
segmented line tool was used to measure track lengths. Average velocity was plotted as a
histogram and fit to a Gaussian distribution. The mean and standard deviation are
reported here. Using methods that we have previously outlined (Thompson et al., 2013),
cumulative frequency plots were generated for run lengths corrected for microtubule
track length effects (through resampling of the data) and reported here (99% confidence
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level of data resampling repeated 10,000 times). Statistical significance was determined
as previously described (Thompson et al., 2013). All data sets are comprised of data
collected on different days (No Tau, N = 10; WT, N = 10; Y18E, N = 10).
Statistics For the motor motility assay average velocities for events were fit to a Gaussian
distribution. The mean of the average velocities and standard deviation of those velocities
are reported here. It has been shown that motor run length is affected by the length of the
track (Thompson et al., 2013). Differences in microtubule track length that might lead to
underestimation of motor run length were corrected using previously published work
(Thompson et al., 2013). Average run lengths were determined using a bootstrapping
method where data was resampled with replacement (for the size of the data set) 10,000
times (Thompson et al., 2013). The standard deviation in these values is reported.
Statistical significance was determined as previously described by comparing resampled
data for the run length (difference between observed and control run lengths) to a null
hypothesis (Thompson et al., 2013).
For the in vitro and dynamics assays, the percentage of events that were static or
diffusive are reported for 14 experiments. The error bars represent the standard deviation
in the percentage of static or diffusive events across 14 separate experiments.
Significance was determined using Fisher’s Exact Test (a variation of a Chi-squared test
which calculates an exact P-value) best used when the sample size is small.
Like the in vitro dynamics assays, the ex vivo dynamics assay reports the
percentage of static or diffusive events for a dataset made up of 5 experiments. The error
bars are also the standard deviation in the percentage of static or diffusive events across 5
experiments. Because of the larger sample size, significance was determined using a Chi-
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squared test with Yates’ correction to improve the P-value approximation of the Chisquared test.
The TIRF binding assay reports the average intensity per unit length at each
concentration imaged. The error bars represent the standard deviation in intensity at each
concentration over 4 experiments.
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Figures

Figure 2. 1 Representative kymographs of kinesin-1 motility.
TIRF microscopy was used to observe kinesin-1 motility was in the absence of Tau
and in the presence of unlabeled or Alexa 488 labeled WT and Y18E 3RS-Tau
(200 nM (1:5, Tau:tubulin)). Continuous (A), Run-Pause-Run (B) and PauseTerminate (C) events were observed under all conditions.
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Figure 2.2 Diagram of motility assays with cumulative frequency plots of run
lengths (mean ± SD) for kinesin-1 in the absence and presence of 3RS-Tau.
A) Flow chambers were passivated with PEG-silane (blue) before tubulin antibodies
(black) were used to adhere paclitaxel stabilized microtubules (green). Q-dot labeled
kinesin-1 (purple/red) motility was observed on undecorated or label/unlabeled Tau
(yellow) decorated microtubules. Inset: Unlabeled microtubules coated with 200 nM
Alexa 488 labeled Tau. B) On undecorated microtubules, kinesin-1 had a run length of
1.64 ± 0.50 m. Introduction of both unlabeled (C) and labeled (D) WT 3RS-Tau,
significantly reduced kinesin-1’s run length to 0.99 ± 0.23 and 0.99 ± 0.24 m (p <
0.05). In the presence of unlabeled (E) and labeled (F) Y18E 3RS-Tau, kinesin-1’s run
length was significantly increased to 1.37 ± 0.39 m (p < 0.05) and 1.35 ± 0.40 m (p
< 0.05), respectively. Introduction of negative charge reduced Tau’s ability to inhibit
kinesin-1 motility and led to a significant increase in run length (Supplemental Table
S2.2). Experiments: 10.
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Figure 2.3 Comparison of WT and Y18E 3RS-Tau behavior on Taxol stabilized
microtubules at high concentration.
A) Representative kymographs show the different types of behaviors that can be
observed. Tau can bind statically (Static: horizontal lines) while interacting with the
microtubule or exhibit dynamic binding along the microtubule surface (Dynamic:
jagged lines). Tau can also switch between these states (Switch). B) Bar graph
comparing the percentage (± SD) of static to dynamic events for WT and Y18E 3RSTau. For WT 3RS-Tau, 77.1 ± 4.2% of events were static while Y18E 3RS-Tau’s
equilibrium was shifted towards the dynamic state (47.7 ± 5.0% static events). (****
denotes a statistically significant difference of p < 0.05). Events: WT = 388, Y18E =
235 from eight experiments.
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Figure 2.4 Comparison of TIRF binding assays.
TIRF binding assays for WT (N = 4), Y18A (N = 3), Y18E (N = 3) and dE (N
= 3) 3RS-Tau. WT 3RS-Tau had a KD (mean ± SD) of 150 ± 126 nM, Y18A
3RS-Tau had a KD of 331 ± 100 nM, Y18E 3RS-Tau had a KD of 700 ± 318 nM
and dE 3RS-Tau had a KD of 902 ± 266 nM. The affinity of Tau for the
microtubule surface decreases with the introduction of increasing negative
charge at Y18.
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Figure 2.5 The behavior of comparable bound fractions of WT, Y18A,
Y18E and dE 3RS-Tau on paclitaxel-stabilized microtubules.
A) Representative kymographs show both dynamic (jagged line) and static
binding along the microtubule surface (horizontal lines). B) Bar graph
comparing the percentage of static to dynamic events (percentage ± SD) for each
Tau construct. Introduction of negative charges at Y18 and T17 shifted the
equilibrium between the static and dynamic states towards the dynamic state.
(****) denotes a statistically significant difference of p < 0.05. Events: WT =
566 (N = 12), Y18A = 320 (N = 5), Y18E = 472 (N = 4), and dE = 220 (N = 5).
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Figure 2.6 Static and dynamic (arrow) binding events with the axoplasm.
Squid giant axon axoplasm samples were used to image WT, Y18A and Y18E 3RSTau interactions (500 pM Alexa 488 labeled Tau, green) with axonal microtubules
(200 nM Alexa 568 labeled Tau, red). Tau binds both statically and dynamically under
physiological conditions.
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Figure 2.7 Tau’s binding equilibrium between static and
dynamic states is maintained ex vivo.
Bar graph comparing the percentage (± SD) of static to dynamic
events for Y18E and Y18A 3RS-Tau in the axoplasm
preparation. As observed in vitro (Figures 3 and 5), a shift in
Tau’s equilibrium towards the dynamic state was observed upon
introduction of negative charge at Y18. ****:p < 0.05. Events:
Y18A = 972 (N = 5), WT =1129 (N = 4), Y18E = 757 (N = 5).
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Figure 2.8 Model of Tau regulation.
Results from our work here indicate that Y18 phosphorylation (yellow) not only
prevents PP1 activation induced by exposed PAD (light blue) (Kanaan et al., 2012),
but also stabilizes Tau (blue) in the dynamic state, allowing for continued kinesin-1
(red) mediated cargo transport. On the other hand, Y18 dephosphorylation would
shift Tau’s equilibrium towards the more inhibitory static state while allowing PAD
activation of PP1 (pink) upon exposure. PP1 would then dephosphorylate and activate
GSK-3β (orange), which in turn phosphorylates kinesin-1 light chains and promotes
dissociation from its transported cargoes. Thus, misregulation of Tau’s dynamic
equilibrium could promote neuronal degeneration by compromising localized
delivery of kinesin-1 cargoes.
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Table S2.1: Tau Labeling Efficiencies
Percent (%) Labeled

Labeling efficiencies for all Tau constructs used in all in vitro and ex vivo
experiments. Alexa 488 labeled Tau was used in in vitro and ex vivo dynamics assays.
Alexa 568 labeled Tau was also used in ex vivo dynamics assays. Alexa 532 labeled
Tau was used for in vitro binding assays.

86

Table S2.2: Kinesin-1 Behavior in the Presence and Absence of 3RS-Tau Constructs

Data from in vitro kinesin-1 motility assays. Observed run lengths (Xobserved) and
microtubule lengths (Lobserved) were used to determine the corrected run length
(Xcorrected) following previously described methods (Thompson et al., 2013). Median
p-values for data sets compared to the no Tau condition were calculated using a
previously detailed resampling method (Thompson et al., 2013). Average velocities
for kinesin-1 under all conditions tested. There was no change in velocity in the
presence and absence of Tau.
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Table S2.3: Behavior of 3RS-Tau Constructs in all Experimental Conditions

Data from in vitro and ex vivo dynamics assays along with in vitro binding assays.
Spike Experiments: WT static dwell times were best fit to a two phase exponential
function which revealed two populations of events with long and short dwell times
(amplitudes given in table). Y18E static dwell times were best fit to a single
exponential function one with one average dwell time. Dynamic dwell times were best
fit to single exponential functions. In vitro binding assays: Affinity (KD) was
determined by plotting the average intensity Alexa 532 3RS-Tau per unit length of
microtubule vs Tau concentration. These plots were normalized to max average
intensity and fit to one site-specific binding with Hill slope curves. Comparable bound
fraction Experiments: Comparable bound fractions were determined based on in vitro
binding assays. All static dwell times were best fit to two phase exponential functions
with both a long and short average dwell time. All dynamic dwell times were best fit
to single exponential functions. Ex vivo dynamics assays: all dwell times were best fit
to single exponential functions.
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Figure S2.1 Cumulative frequency plots of uncorrected kinesin-1 run lengths in
the presence of unlabeled and Alexa 488 labeled WT 3RS-Tau.
Average run lengths were calculated through data resampling (10,000 times) as
previously described (Thompson et al., 2013).
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Figure S2.2 Cumulative frequency plots for WT and Y18E 3RS-Tau static and
dynamic dwell times at high concentration.
All plots show 95% confidence bands as dotted lines. A) WT 3RS-Tau static dwell
times were best fit to a two phase exponential function. This revealed an average long
static dwell time of 15.7 s and a short static dwell time of 1.4 s (R2 = 0.9988; N =
299). B) Y18E 3RS-Tau static dwell times best fit a one phase exponential function
and had an average dwell time of 14.5 s (R2 = 0.9960; N = 112). C) Dynamic dwell
times for WT 3RS-Tau were fit to a one phase exponential function with an average
dwell time of 1.6 s (R2 = 0.9931; N = 89). D) Y18E 3RS-Tau dynamic dwell times
were also fit to a one phase exponential function with an average of 1.9 s (R2 =
0.9883; N = 123).
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Figure S2.3 Overlay of static and dynamic cumulative frequency plots for WT and
Y18E 3RS-Tau spike experiments.
WT 3RS-Tau static events were best fit to a two phase exponential function while Y18E
3RS-Tau was best fit to a one phase exponential function. Dynamic dwell times for both
WT and Y18E 3RS-Tau were best fit to one phase exponential functions. Plots show
95% confidence bands as dotted lines.
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Figure S2.4 Cumulative frequency plots for WT, Y18A, Y18E and dE 3RS-Tau
dynamic dwell times.
All dynamic dwell times were best fit to one phase exponential functions with 95%
confidence bands as dotted lines. A) WT 3RS-Tau had an average dwell time of 2.8 s
(R2 = 0.9977). B) Y18A 3RS-Tau had an average dwell time of 1.7 s (R2 = 0.9934). C)
Y18E 3RS-Tau had an average dwell time of 1.7 s (R2 = 0.9945). D) dE 3RS-Tau had
and average dwell time of 3.2 s (R2 = 0.9960). There were no notable changes in
dynamic dwell times for WT and 3RS-Tau constructs.
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Figure S2.5 Cumulative frequency plots for WT, Y18A, Y18E and dE 3RS-Tau
static dwell times.
All static dwell times were best fit to two phase exponential functions with 95%
confidence bands as dotted lines. A) WT 3RS-Tau had a long dwell time of 13.8 s and
a short dwell time of 2.1 s (R2 = 0.9991). B) Y18A 3RS-Tau had a long dwell time of
12.2 s and a short dwell time of 2.2 s (R2 = 0.9985). C) Y18E 3RS-Tau had a long
dwell time of 9.5 s and a short dwell time of 1.8 s (R2 = 0.9990). D) dE 3RS-Tau had
a long dwell time of 14.4 s and a short dwell time of 6.8 s (R2 = 0.9986). There were
no notable changes in static dwell times (both long and short) for WT and 3RS-Tau
constructs.
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Figure S2.6 Cumulative frequency plots for Y18A and Y18E 3RS-Tau ex vivo
dwell times.
All dwell times were best fit to single exponential functions with 95% confidence
bands as dotted lines. A) Y18A 3RS-Tau had a static dwell time of 0.7 s (R2 =
0.9859), (B) WT 3RS-Tau had a static dwell time of 0.5 s (R2 = 0.9609) and C) Y18E
3RS-Tau had a static dwell time of 0.8 s (R2 = 0.9966). D) Y18A 3RS-Tau had a
dynamic dwell time of 0.9 s (R2 = 0.9785), (E) WT 3RS-Tau had a dynamic dwell
time of 0.4 s (R2 = 0.9578) and (F) Y18E 3RS-Tau had a dynamic dwell time of 1.3 s
(R2 = 0.9924). Static and dynamic dwell times for Y18A, WT and Y18E 3RS-Tau are
not appreciably different. However, these dwell times were shorter than those found in
the in vitro assays due to the increased ionic strength found under physiological
conditions.
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Supplemental Movies
Movie S1 Sample motility assay for kinesin-1 in the presence of labeled WT 3RSTau. TIRF microscopy was used to observe the motility of Q-dot 655 labeled kinesin-1
on paclitaxel stabilized microtubules coated with Alexa 488 labeled WT 3RS-Tau (200
nM; 1:5, Tau:tubulin). 500 frames were recorded at 5 fps. Shown here at 15 fps. Arrows
indicate runs. Data was analyzed using ImageJ as described.
Movie S2 Sample motility assay for kinesin-1 in the presence of unlabeled Y18E
3RS-Tau. We observed the motility of Qdot 655 labeled kinesin-1 on rhodamine labeled,
paclitaxel stabilized microtubules coated with Y18E 3RS-Tau with the same ratio as
above (Supplemental Movie S1). 500 frames were recorded at 5 fps. Shown here at 5 fps.
Arrows indicate runs. Data was analyzed using ImageJ as described previously
(Supplemental Movie S1).
Movie S3 Sample in vitro dynamics assay. Unlabeled WT 3RS-Tau at 200 nM (1:5;
Tau:tubulin) spiked with Alexa 488 labeled WT 3RS-Tau (500 pM) behavior on
rhodamine labeled microtubules. Arrows indicate binding events. 1000 frames were
recorded at 10 fps shown here at 5 fps. Data was analyzed as described in the Methods
sections.
Movie S4 Sample in vitro dynamics assay. Alexa 488 labeled Y18E 3RS-Tau was
imaged at 1:3000 ratio with rhodamine labeled microtubules. Arrows indicate binding
events. Data was acquired and analyzed as described in Supplemental Movie S3.
Movie S5 Sample ex vivo dynamics assay. Squid axoplasm was used to observe the
behavior of Alexa 488 labeled Y18A 3RS-Tau on Alexa 568 labeled Y18A 3RS-Tau
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coated microtubules. Images were collected at 3 fps. 100 frames were collected for each
channel. Upward pointing arrows indicate dynamic events while downward pointing
arrows indicate static events.
Movies can be found at http://www.molbiolcell.org.
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CHAPTER 3: STRUCTURAL CHANGES UNDERLIE STATIC AND DIFFUSIVE
TAU BINDING ON THE MICROTUBULE SURFACE
3.1 Abstract
The neuronal microtubule associated protein Tau is integral to the regulation of
axonal transport and has been shown to carry out numerous functions including
regulation of kinesin-1 cargo delivery. Kinesin-1 cargo transport is regulated through Tau
participation in signaling cascades and direct modulation of motor movement. Our recent
observation that N-terminal phosphorylation regulates Tau static-diffusive binding
equilibrium and ability to modulate kinesin-1 motility, indicates that long range structural
changes underlie static vs diffusive binding. This observation, coupled with solution and
microtubule bound studies to determine Tau structure, led us to hypothesize that Tau
binds the microtubule in multiple conformations. To address the challenge of observing
structural change for a dynamically bound protein, we used total internal reflection
fluorescence (TIRF) microscopy and alternating laser excitation (ALEX) to develop a
three color single-molecule fluorescence resonance energy transfer (smFRET) assay.
With this assay we have imaged the shortest isoform (3RS) of Tau in both the static and
diffusive state on the microtubule surface. Using N- and C-termini dual labeled 3RS-Tau,
we correlate changes in FRET efficiency with behavioral changes to demonstrate the
efficacy of our approach. Our results show that the N- and C-termini interact while Tau is
bound statically while this interaction is reduced in the diffusive state.
3.2 Introduction
Within the axon the molecular motor based movement of cargo along
microtubule tracks (fast axonal transport, FAT) is regulated by complex signaling
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pathways and many microtubule associated proteins (MAPs). The MAP Tau has been
shown to carry out numerous functions during FAT including regulation of kinesin-1
based cargo delivery (Kanaan et al., 2012). Tau mutations, aberrant isoform expression,
and modification all lead to the disruption of FAT and are part of the pathology
associated with Alzheimer’s disease and other Tauopathies (Martin et al., 2011; Ling,
2018). Six Tau isoforms are expressed in the adult brain and arise from alternative
splicing of a single gene (Andreadis, 2005; Ballatore et al., 2007). These isoforms differ
based on the number of C-terminal microtubule binding repeats (MBRs, 3-4) and Nterminal acidic inserts (0-2) (Andreadis, 2005; Ballatore et al., 2007). All isoforms have
an N-terminal phosphatase activating domain (PAD) and proline rich region (PRR)
(Margeat et al.; Ballatore et al., 2007). All isoforms are subject to post-translational
modifications including phosphorylation (Lee et al., 2004; Andreadis, 2005; Ballatore et
al., 2007; Martin et al., 2013b).
Tau regulates kinesin-1 based cargo transport through participation in signaling
cascades and direct inhibition of motor motility (McVicker et al., 2011; Kanaan et al.,
2012; Stern et al., 2017). Tau’s direct inhibition of kinesin-1 motility is well documented
(Vershinin et al., 2007; Dixit et al., 2008; McVicker et al., 2011; Hoeprich et al., 2014).
We have shown that the level of inhibition is dependent on Tau isoform and microtubule
lattice structure (McVicker et al., 2011). The shortest isoform, 3RS-Tau is more
inhibitory to kinesin-1 on paclitaxel stabilized microtubules than the longest isoform
4RL-Tau (McVicker et al., 2011). These isoform differences extend to Tau’s behavior on
the microtubule. Tau has been shown to bind the microtubule in a static-diffusive state
equilibrium (Dixit et al., 2008; Hinrichs et al., 2012; McVicker et al., 2014) which we
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have demonstrated differs with isoform (McVicker et al., 2014) and correlates with the
isoform’s ability to inhibit kinesin-1 motility (McVicker et al., 2011; McVicker et al.,
2014). 3RS-Tau which is more inhibitory to kinesin-1 favors static binding on paclitaxel
microtubules while the less inhibitory isoform 4RL-Tau is shifted towards diffusive
binding (McVicker et al., 2014).
The PAD has been shown to facilitate Tau’s interaction with protein
phosphatase 1 (PP1) which in turn regulates cargo delivery (Kanaan et al., 2012). Fyn
kinase mediated phosphorylation of tyrosine 18 (Y18), the last amino acid in the PAD,
prevents the Tau-PP1 interaction (Kanaan et al., 2012). The behavioral and functional
differences we observed for 4RL- and 3RS-Tau led us to ask whether Tau’s binding
equilibrium could be regulated by the cell. We observed that phospho-mimetics of Y18
3RS-Tau induce a shift towards diffusive state binding and reduce both inhibition of
kinesin-1 and Tau’s affinity for the microtubule surface (Stern et al., 2017).
Phosphorylation within the MBRs and adjacent regions has been shown to reduce
microtubule binding affinity (Biernat et al., 1993) but our observation that this occurs
with phosphorylation in the N-terminal projection region which does not bind the
microtubule (Goode et al., 2000; Stern et al., 2017), indicates that long range structural
changes may underlie static vs diffusive binding. Furthermore, phosphorylation mediated
control of both Tau’s signaling cascade participation and ability to inhibit kinesin-1
suggests a link between structural and functional regulation.
Recently, two dynamic folded conformations have been identified for Tau in
solution (Jeganathan et al., 2006; Elbaum-Garfinkle and Rhoades, 2012). While they
differ in their finer details, they show that a folded conformation is stabilized by N- and
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C-termini interactions (Jeganathan et al., 2006; Elbaum-Garfinkle and Rhoades, 2012).
To date structures underlying static and diffusive microtubule binding have not been
observed. Initial transmission electron microscopy (TEM) studies of microtubule bound
Tau showed no distinct bound structure (Cleveland et al., 1977). Hirokawa et al. (1988)
performed cryo-EM studies of densely packed Tau-microtubule pellets where Tau
projections from the microtubule surface were clearly visible (Hirokawa et al., 1988), but
the microtubule bound portion of the protein could not be resolved. More recent cryo-EM
work with Tau and MAP2c, found that both proteins bind along microtubule
protofilament ridges (Al-Bassam et al., 2002). Santarella et al. (2004) determined that
Tau binds to α-tubulin subunits however, their study suggested that Tau binds both along
and across protofilaments. Though these studies furthered our understanding of the Taumicrotubule interaction, they also show that Tau decorated microtubules appear to have a
‘fuzzy’ coat (Al-Bassam et al., 2002; Santarella et al., 2004). This ‘fuzziness’ indicates
that the portions of Tau that do not interact with the microtubule surface are free to adopt
multiple conformations (Santarella et al., 2004) that cryo-EM techniques cannot resolve.
This is further supported by recent nuclear magnetic resonance (NMR) studies which
suggest that when Tau is bound to the microtubule local folding occurs in MBR interrepeat regions (Kadavath et al., 2015). These regions are connected by a flexible linker
indicating that Tau may have the ability to adopt multiple conformations while bound to
the microtubule (Kadavath et al., 2015).
We propose a model of dynamic binding where Tau’s structure while statically
bound is distinct from its diffusively bound structure. These structural changes create a
conformational equilibrium underlying a behavioral equilibrium. To address the
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challenge of observing structural change for a dynamically bound protein, we have
developed a three color single-molecule fluorescence resonance energy transfer
(smFRET) (Roy et al., 2008) assay. This assay allows us to image dual labeled Tau
interacting with labeled microtubules. Using total internal reflection fluorescence (TIRF)
microscopy and alternating laser excitation (ALEX) (Kapanidis et al., 2005), we have
imaged both statically and diffusively bound Tau. From these data we can correlate
changes in FRET efficiency with behavioral changes. Here we demonstrate the efficacy
of our approach using N- and C-termini dual labeled 3RS-Tau. Our results show that the
N- and C-termini interact while Tau is bound in the static state and this interaction is
reduced in the diffusive state.
3.3 Methods
All work was done with 1X Brinkley’s Reassembly Buffer 80 (BRB80; 80 mM
PIPES, 1 mM EGTA, 1 mM MgCl2, pH 6.9 at room temperature) unless otherwise noted
(Stern et al., 2017).
Tau Construct Generation Our N&C 3RS-Tau smFRET construct was generated by
introducing the following changes: T17C, C322I, S346C using the QuikChange II XL
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) (Figure 3.1A).
Similarly, N 3RS-Tau and C 3RS-Tau constructs were generated using the QuikChange
Mutagenesis Kit to introduce cysteines at T17 and S346 respectively in a C322I construct
(Figure 3.1A). WT 3RS-Tau and all Tau constructs were expressed in BL21CodonPlus(DE3)-RP Escherichia coli cells (Stratagene, La Jolla, CA) and purified using
Q and SP Sepharose (Sigma-Aldrich, St. Lois, MO) affinity column chromatography as
previously described (McVicker et al., 2011; McVicker et al., 2014). After purification,
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samples were dialyzed against 1X BRB80. Protein concentrations were determined using
the bicinchonic acid (BCA) assay (Pierce, Rockford, IL) and WT 3RS-Tau standards.
SDS PAGE gels (Bio-Rad, Hercules, CA) were used to validate concentrations.
Tau Construct Labeling smFRET Construct N&C 3RS-Tau was dual labeled with the
FRET pair Alexa Fluor® 488/647 (Alexa Fluor® 488 C5 Maleimide and Alexa Fluor® 647
C2 Maleimide; Invitrogen Molecular Probes, Carlsbad, CA). N&C 3RS-Tau was
incubated in 4M guanidine hydrochloride (GndHCl), 1X phosphate-buffered saline (PBS)
pH 7.4 (diluted from 10X PBS pH 7.4; Gibco® by Life Technologies, Grand Isle, NY)
and 10 fold molar excess dithiothreitol (DTT) for 10 min at 37 oC. Following this
incubation, a 2 ml 7K MWCO ZebaTM spin desalting column (Peirce, Rockford, IL) was
used to remove reducing agents. N&C 3RS-Tau was then incubated with 10 fold molar
excess of Alexa Fluor® 647 in the presence of 1 mM sodium bicarbonate (to raise the pH
above 7 and improve labeling) for 24 hr in the dark at room temperature. Two fold molar
excess Alexa Fluor® 488 was then added for an additional 24 hr incubation. Excess
fluorophore was removed by three rounds of dialysis against 1X BRB80. The protein
concentration was determined using both the Modified Lowry Assay (Peirce, Rockford,
IL) and densitometry performed on SDS PAGE gels. Labeling efficiency was determined
as described previously (Stern et al., 2017) using the extinction coefficients Alexa Fluor®
488 – 71,000 cm-1M-1 at 493 nm and Alexa Fluor® 647 – 270,000 cm-1M-1 at 652 nm.
Labeling efficiency was Alexa 488: 26%, Alexa 647: 79%.
WT, N and C 3RS-Tau Constructs WT 3RS-Tau and both Tau constructs were singly
labeled with Alexa Fluor® 647 and 488. For Alexa Fluor® 647 labeling was carried out
following the method detailed for dual labeling except that there was no 24 hr Alexa
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Fluor® 488 incubation. For Alexa Fluor® 488, labeling was carried out at as detailed
previously (McVicker et al., 2014; Stern et al., 2017). Briefly, constructs were incubated
with 10 fold molar excess DTT for 2 hr at room temperature before the DTT was
removed with a desalting column. Protein was then incubated with 5 fold molar excess
fluor at room temperature before excess fluor was removed with a desalting column.
Protein concentration and labeling efficiency was determined as described previously
(Stern et al., 2017) using the extinction coefficients listed above. Labeling efficiency was
Alexa 488 – WT: 42%, N: 50%, C: 75%; Alexa 647 – WT: 60 %, N: 34%, C: 47 %.
High, Intermediate and Low FRET Oligomer Design The R0 for the FRET pair Alexa
488/647 was calculated using the equation:
1:

Where K2 is the orientation factor (assumed to be 2/3) (Shrestha et al., 2015), ϕD is
quantum yield of donor (0.92) (Johnson, 2010) and J(𝜆) is the overlap integral of donor
emission and acceptor excitation spectra defined as:
2:

Where εA is the acceptor extinction coefficients and FD(𝜆) is the normalized donor
emission spectrum both measured using a fluorimeter to determine the excitation and
emission spectra of Alexa 488 and 647 at 200 nM (Supplemental Fig. S2). The R0 was
determined to be 52.7 Å.
Based on the R0 DNA oligomers were developed for High, Intermediate and Low FRET
states.

The

High

FRET

control

oligomer
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was

designed

as

follows:

5’-

/Alexa488/TCCCACCTGTCCATGCCAGCCT/Biotin/-3’

and

5’-

AGGCTGGCATGGACAGGTGGGA/Alexa647/-3’ (Integrated DNA Technologies,
Coralville, IA) with a FRET pair spacing of 24 Å. The Low FRET control oligomer was
designed using the same sequence for the High FRET oligomer as follows: 5’/Alexa488/TCCCACCTGTCCATGCCAGCCT/Biotin/-3’

and

5’/Alexa647/AGGCTGGCA TGGACAGGTGGGA-3’ (Integrated DNA Technologies,
Coralville, IA) with a FRET pair spacing of 73 Å. The Intermediate FRET control was
designed with the sequence: 5’/Alexa488/AGGCTGGCATGGACGT/Biotin/-3’ and 5’/Alexa647/ACGTCCATG CCAGCCT-3’ (Integrated DNA Technologies, Coralville, IA)
with a FRET pair spacing of 53 Å.
Tubulin Purification and Labeling Tubulin was purified as previously described from
bovine brain obtained from Vermont Livestock & Slaughter (Ferrisburgh, VT)
(McVicker et al., 2014). For imaging in our three color system, purified tubulin was
labeled with Alexa Fluor® 405 using methods developed by Hyman et al. (Hyman et al.,
1991). Purified tubulin (20-25 mg) was polymerized at 37 oC for 30 min. Following
polymerization, microtubules were layered on a warm high cushion buffer (0.1 M
NaHEPES (pH 8.6) (Sigma-Aldrich, St. Lois, MO), 1 mM MgCl2, 1 mM EGTA, 60%
(v/v) glycerol) and pelleted at 40,000 rpm, 45 min, 35 oC in an OptimaTM TLX
Ultracentrifuge (Beckman, Pasadena, CA). The supernatant was aspirated and the
cushion surface was washed with warm label buffer (0.1 M NaHEPES (pH 8.6), 1 mM
MgCl2, 1 mM EGTA, 40% (v/v) glycerol). The cushion was then aspirated and the pellet
resuspended in warm label buffer. The resuspended microtubules were incubated with 10
fold molar excess Alexa Fluor® 405 for 1 hr at 37 oC with vortexing.
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To quench labeling, an equal volume of stop buffer (2X BRB80, 100 mM LGlutamic acid potassium salt monohydrate (K-glutamate; Sigma-Aldrich, St. Lois, MO),
40% (v/v) glycerol) was added to the microtubule/dye mixture and incubated for 5 min at
37 oC. The quenched mixture was placed on a warm low cushion buffer (60% (v/v)
glycerol, 1X BRB80) and centrifuged at 80,000 rpm, 35 oC for 20 min. The supernatant
was discarded and warm 1X BRB80 (37 oC) was used to wash the cushion before the
pellet was resuspended in ice cold 1X depolymerization buffer (50 mM K-glutamate, 5
mM MgCl2, pH 7.0) and incubated for 30 min at 4 oC. Depolymerized tubulin was
centrifuged at 80,000 rpm, 2 oC for 10 min. Supernatant was recovered. 1X BRB80, 4
mM MgCl2 and 1 mM GTP were added to the supernatant before the mixture was
incubated on ice for 3 min. This mixture was then incubated at 37 oC for 2 min before ½
volume warm glycerol (33% v/v) was added. The solution was incubated for a further 30
min at 37 oC. Polymerized tubulin was layered onto warm low cushion buffer and
pelleted at 80,000 rpm, 20 min, 37 oC. The resulting microtubule pellet was resuspended
in ice cold 1X BRB80 and incubated at 4 oC for 30 min. Depolymerized tubulin was
centrifuged a final time at 80,000 rpm, 10 min, 2 oC. Protein concentration was
determined using Beer-Lambert’s law and the tubulin extinction coefficient of 110,000
cm-1M-1 at 280 nm. Labeling efficiency was determined in the same manner using the
Alexa 405 extinction coefficient of 35,000 cm-1M-1 at 401 nm. Tubulin concentration was
validated using SDS PAGE gels.
Slide Coating and Chamber Construction Biotin-PEG coating Coverslips (Marienfeld
High Precision Microscope Cover Glass No. 1.5H (tol. ± 0.5 µm), Azer Scientific,
Morgantown, PA) were methanol washed and plasma cleaned as previously described
105

(McVicker et al., 2014; Stern et al., 2017). Cleaned slides were then incubated with an
amino silane mixture (94 % methanol, 5 % acetic acid and 1 % N-(2-aminoethyl)-3aminopropyltrimethoxysilane (MilliporeSigma, Billerica, MA)) for 15 min before a 30
sec sonication and additional 15 min incubation (Joo and Ha, 2012b). Slides were rinsed
in ddH2O and dried. Following this, slides were incubated with a PEG solution (0.57 mM
mPEG-Biotin (Laysan Bio Inc, Arab, AL), 22 mM mPEG-SC (Laysan Bio Inc, Arab,
AL) in 0.1 M NaHCO3 (Sigma-Aldrich, St. Lois, MO) per slide) overnight in a
humidifying chamber (Joo and Ha, 2012b). Slides were then washed with ddH2O and
stored at -20 oC until used. Flow chambers were constructed on the day of the experiment
using double sided tape.
Silane-PEG coating Glass coverslips were silane-PEG coated as previously described
(Stern et al., 2017). Briefly, methanol washed slides were plasma cleaned and incubated
in a silane mixture (97% toluene (Sigma-Aldrich, St. Lois, MO), 2% 2methoxy(polyethyleneoxy)propyltrimethoxysilane (Gelest Inc., Morrisville, PA), and 1%
butylamine (Acros Organics, New Jersey, USA )) with flowing nitrogen gas for 90 min
(Lowndes and Nelson, 2013). Coverslips were then washed in toluene, dried and cured
with flowing nitrogen gas for 30 min. Flow chambers were constructed using ARTUS
shims (ARTUS, Eaglewood, NJ) and Norland optical adhesive (Norland Products,
Cranbury, NJ) as previously described (Stern et al., 2017).
Microtubule Polymerization Paclitaxel stabilized Purified, unlabeled tubulin was
clarified by ultracentrifugation (20 min, 95,000 rpm, 4oC). Clarified tubulin was mixed
with Alexa Fluor® 405 labeled tubulin at a 1:7 (labeled:unlabeled) ratio and 1 mM GTP
(Sigma-Aldrich, St. Lois, MO). Microtubules were polymerized for 20 min at 37oC
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(McVicker et al., 2014; Stern et al., 2017). Following polymerization, microtubules were
stabilized with 20 µM paclitaxel (paclitaxel; Sigma-Aldrich, St. Lois, MO). Postclarification tubulin concentration was calculated using the tubulin extinction coefficient
of 110,000 cm-1M-1 at 280 nm.
GMPCPP stabilized Clarified tubulin was mixed with Alexa Fluor® 405 labeled tubulin
in a 1:7 (labeled:unlabeled) ratio and 20 µM guanosine-5’-[(α,β)-methyleno]triphosphate
(GMPCPP; Jena Bioscience, Jena, Germany). Microtubules were polymerized by
incubating small volumes of the mixture stepwise at 37 oC with 20 min incubations
between additions (McVicker et al., 2014). Post clarification tubulin concentration was
determined as described above.
DNA Oligomer Assay 1X BRB80 (pH 7.4 w/KOH) was used to prepare all assay
buffers. Chambers were washed with 1 mg/mL biotinylated BSA (Sigma-Aldrich, St.
Lois, MO) for 5 minutes. Chambers were then incubated with one chamber volume 0.2
mg/mL streptavidin (Sigma-Aldrich, St. Lois, MO) (diluted in 1 mg/mL BSA (SigmaAldrich, St. Lois, MO)) for 5 minutes before one chamber volume of 50 pM desired DNA
oligomer (diluted in 1 mg/mL biotinylated BSA) was flown in for 5 minutes. Chambers
were washed with 2X chamber volume 1mg/mL biotinylated BSA to remove nonadherent oligomers. To prevent drying, chambers were sealed with grease. An inverted
Eclipse Ti Microscope (Nikon, Melville, NY) with a 100X PlanApo objective lens (1.49
NA) and auxiliary 1.5X magnification and two iXON Ultra EMCCD cameras (Andor,
Belfast, N-IRL) running NIS Elements v4.51 (Nikon, Melville, NY) were used to
perform TIRF microscopy with alternating laser excitation. Alexa 488/647 labeled
oligomers were imaged by alternating exposure with 640 nm and 488 nm argon lasers
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and 525/50 and 655 LP emission filters. Three hundred frames were collected at room
temperature at 0.2 s, 0.11 µm/pixel.
Behavioral and Intermolecular FRET Assays For both assays, washes and incubations
were performed with BRB80+OS (BRB80 supplemented with a previously published
oxygen scavenging system (McVicker et al., 2011)) supplemented with 20 µM paclitaxel
and 1.5 mM (±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox)
(Sigma-Aldrich, St. Lois, MO) (Joo and Ha, 2012a). Silanized flow chambers were
incubated with monoclonal anti-β III (neuronal) tubulin antibodies (Sigma-Aldrich, St.
Lois, MO) at 33 µg/mL for 5 min followed by a 5 min 2X chamber volume wash with 2
mg/mL BSA (Sigma-Aldrich, St. Lois, MO) (McVicker et al., 2014).
Behavioral Assay Chambers were incubated for 12 min with paclitaxel stabilized, Alexa
405 labeled microtubules diluted to 1 – 1.5 µM in 333 – 500 pM N, C or WT 3RS-Tau
constructs. Finally, chambers were washed with 333 - 500 pM N, C or WT 3RS-Tau for
2-4 min to remove non-adherent microtubules. All Tau and microtubule dilutions were
made in warm (37oC) BRB80+OS with paclitaxel and Trolox. Imaging was done using
the system described for the DNA oligomer assay. Alexa 405 labeled tubulin was excited
and imaged with a 405 nm argon laser and a 450/50 emission filter. For microtubules, 10
frames were collected at room temperature at 0.3 s, 0.11 µm/pixel. Tau was imaged using
the laser and filter combinations described for the DNA oligomers. 300 frames were
collected at room temperature at 0.2 s, 0.11 µm/pixel.
Intermolecular smFRET Assay This assay was prepared using the buffers and chamber
preparation described for the behavioral assay above. Chambers were incubated for 12
min with paclitaxel stabilized, Alexa 405 labeled microtubules diluted to a final
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concentration of 1-1.5 uM. An equal mixture of singly labeled (Alexa 488 and 647) N
and C 3RS-Tau was flown into the chamber at 1 nM (20X the concentration used for
smFRET experiments) before imaging. Imaging was carried out using the system detailed
in the DNA oligomer assay and data was collected as for the behavioral assay.
smFRET Assay For imaging, washes and incubations were performed with BRB80+OS
(BRB80 supplemented with a previously published oxygen scavenging system
(McVicker et al., 2011)) supplemented with 1.5 mM (±)-6-Hydroxy-2,5,7,8tetramethylchromane-2-carboxylic acid (Trolox) (Sigma-Aldrich, St. Lois, MO) (Joo and
Ha, 2012a). Silanized flow chambers (McVicker et al., 2014) were incubated with
monoclonal anti-β III (neuronal) tubulin antibodies (Sigma-Aldrich, St. Lois, MO) at 33
µg/mL for 5 min followed by a 5 min 2X chamber volume wash with 2 mg/mL BSA
(Sigma-Aldrich, St. Lois, MO). Chambers were then incubated for 12 min with paclitaxel
or GMPCPP stabilized, Alexa 405 labeled microtubules diluted to 1.5 µM in 50 pM dual
labeled N&C 3RS-Tau. Finally, chambers were washed with 50 pM dual labeled N&C
3RS-Tau for 2-4 min to remove non-adherent microtubules. All Tau and microtubule
dilutions were made in warm (37oC) BRB80+OS with Trolox. Imaging was done using
the system described for the DNA oligomer assay. Alexa 405 labeled tubulin was excited
and imaged with a 405 nm argon laser and a 450/50 emission filter. For microtubules, 10
frames were collected at room temperature at 0.3 s, 0.11 µm/pixel. Tau was imaged using
the laser and filter combinations described for the DNA oligomers. 300 frames were
collected at room temperature at 0.2 s, 0.11 µm/pixel.
Data Analysis Behavioral Assay Events were tracked using the MTrackJ plugin for FIJI
if they lasted more than three frames, the signal remained within a snap range of 19 x 19
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pixels from one frame to the next (snap range chosen based on maximum diffusive range
of a Tau protein (Konzack et al., 2007)) and the event began and ended on one
microtubule. Tracks were measured and the points were then exported to Excel. These
files were analyzed using a custom MATLAB (R2014b) sliding window analysis script
(Rehan Ali, Unpublished) to calculate mean squared displacement. The mean squared
displacement was used to separate events as either static or diffusive. Diffusion
coefficients and alpha values were calculated for diffusive events (Supplemental Table
S1).
DNA Oligomers Images were analyzed using FIJI (Schindelin et al., 2012). Dual labeled
oligomers were identified using kymographs for the donor and acceptor channels
generated with the Multi Kymograph function. Co-localized events were further
analyzed. Dual labeled events were tracked using MTrackJ from the ImageScience plugin
(v3.0.0; Eric Meijering) for FIJI. Tracks were measured in all channels and track points
were exported to Excel. Points in Excel were further analyzed using MATLAB (R2014b)
to track the event frame by frame within a 3 x 3 pixel area around the central x,y position
provided by the track (Rehan Ali, Unpublished). Local background subtraction was
performed before the average intensity of the event in each frame was calculated.
Average intensities were used to calculate the constants χ and γ using the following
equations:
3:

Where χ is the bleed-through of the donor (
was calculated upon acceptor photo-bleaching.
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) into the energy transfer channel (

)

4:

Where γ is the sensitivity of the system when detecting the acceptor (
donor (

) versus the

) fluorophore was calculated upon acceptor photo-bleaching.

Donor/acceptor fluorophore stoichiometry (S) and efficiency of energy transfer (E) for
each event were calculated as follows:
5:

6:

Intermolecular FRET Assay Alexa 488 and 647 binding events that overlapped or
occurred close to each other, were identified by generating kymographs as for oligomer
analysis. Using the MTrackJ plugin, events were tracked in their respective channels
(data shown from events tracked in the donor channel). Upon measurement of these
tracks in each channel, the points were exported to Excel for further analysis with a
custom MATLAB script as for the behavioral assay. The x,y position associated with
each track was used to identify the event within the image field for calculation of the
corrected intensity as described for the DNA oligomer. These corrected intensities were
then used to calculate average S and E for each event.
smFRET Assay Dual labeled events were identified as described for oligomer analysis.
Identified dual labeled events were further analyzed using the MTrackJ plugin. Events
lasting longer than three frames were tracked using a snap range of 19 x 19 pixels with
bright centroid tracking. Tracks were measured in each channel and were scored static or
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diffusive based on their maximum distance to start as described in Stern et al., (2017).
Points were exported to Excel for further analysis.
The x, y positions provided by the event points were used to identify events in
the image field so that the average corrected intensity of the event in each channel from
frame to frame could be calculated as detailed for oligomer analysis. The average
corrected intensities for static and diffusive events were then used to calculate average S
and E for each event using the equations detailed above.
Statistics Percentages for static and diffusive populations were presented as described for
the behavioral assay in chapter two. Briefly, the standard deviation shown is the spread in
the static and diffusive populations for two experiments.
Average S and E calculations for high, intermediate and low DNA oligomer
constructs are based on the averages of 8 events for each oligomer collected over three
experiments. For intermolecular FRET, average S and E calculations are for averages of
6 events collected over two experiments. Average S and E calculations for Tau are based
on averages of 12 events collected over two experiments for both paclitaxel and
GMPCPP stabilized microtubules. The standard deviation reported for average S and E is
the deviation for total events. Significance was determined for all S and E calculations
using a T-test with Welch’s correction assuming different standard deviations for static
and diffusive events.
3.4 Results
Tau’s behavior is not affected by introduction/removal of cysteine residues or labeling in
the N- and C-termini. To generate our smFRET construct for dual labeling (N&C 3RSTau), we mutated 3RS-Tau’s naturally occurring cysteine to an isoleucine (C322I) and
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introduced cysteines in the N- and C-termini (T17C and S346C) (Figure 3.1A). In order
to ensure that these changes did not affect Tau’s behavior while bound to the microtubule
surface, we generated single cysteine constructs (T17C/C322I and C322I/S346C; Figure
3.1A). These single cysteine constructs were labeled with either Alexa 488 or 647. Using
TIRF microscopy, we observed Alexa 488 and 647 labeled WT, N and C 3RS-Tau bound
to paclitaxel stabilized, Alexa 405 labeled microtubules (Figure 3.1B and 3.2A).
Behavioral assays performed for donor (Alexa 488) labeled N 3RS-Tau (74 ± 4 % static)
and C 3RS-Tau (66 ± 5 % static) revealed no significant differences in binding
equilibrium when compared to WT 3RS-Tau (72 ± 5 % static; P > 0.05) or to each other
(P > 0.05) (Figure 3.2B and Supplementary Table S3.1). We also observed that labeling
with acceptor (Alexa 647) did not have a significant effect (P > 0.05) on binding
equilibrium when comparing N 3RS-Tau (67 ± 5 % static) to C 3RS-Tau (60 ± 5 %
static) or comparing both to WT 3RS-Tau (65 ± 5 % static; P > 0.05) (Figure 3.2B and
Supplemental Table S3.1). Dwell times, diffusion coefficients and alpha values
determined for WT, N, and C 3RS-Tau did not change with fluorophore (Supplementary
Table S3.1).
DNA oligomer constructs demonstrate imaging of high, intermediate and low FRET
states and allow calculation of γ and χ. Based on the R0 (52.7 Å) calculated for our
FRET pair (Alexa 488/647), we designed DNA oligomers to measure high (23 Å, E >
0.9), intermediate (53 Å, E = 0.5) and low (73 Å, E < 0.2) FRET states (Supplemental
Fig. 3.1). These oligomers were imaged using TIRF microscopy and ALEX to test the
system’s ability to image both fluorophores in these different FRET states. Upon acceptor
photo-bleaching (Figure 3.3), χ (donor bleed-through into the acceptor channel) was
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calculated to be 0.021 while γ (differences in detecting donor and acceptor fluorophores)
was calculated to be 0.83. These constants were used to correct all S and E calculations.
For the high FRET oligomer we measured an average S of 0.57 ± 0.09 and an average E
of 1.1 ± 0.23 (24 Å) (Figure 3.4, Supplementary Fig. 3.1). The intermediate FRET
oligomer had average S of 0.63 ± 0.13 and an average E of 0.52 ± 0.11 (52 Å) (Figure
3.4, Supplementary Fig. S3.1). For the low FRET oligomer, we measured an average S of
0.52 ± 0.09 and an average E of 0.14 ± 0.11 (71 Å) (Figure 3.4, Supplementary Fig.
S3.1). These results demonstrate that our system is capable of accurately detecting
changes in fluorophore intensity that correspond to different FRET states.
Intermolecular FRET does not occur at the smFRET imaging concentration. Though our
smFRET imaging concentration (50 pM) results in Tau-microtubule ratio of 1:30,000
(based on a 1.5 µM microtubule imaging concentration), which greatly reduces possible
Tau-Tau interactions on the microtubule surface, interactions may still occur. Such
interactions could result in intermolecular FRET leading to false measurements with our
dual labeled population. To determine if intermolecular FRET occurs, we imaged a
mixture (1:1:1) of Alexa 488 and Alexa 647 singly labeled WT, N and C 3RS-Tau. Using
TIRF microscopy and ALEX, we imaged N and C 3RS-Tau at 1 nM (20X smFRET assay
concentration). Alexa 488 and 647 labeled binding events that overlapped or occurred in
close proximity (Figure 3.5A) were tracked using MTrackJ. Using MATLAB, intensity
values associated with these events were used to calculate both S and E. We observed
that even when binding events overlapped, they had an E of 0.04 ± 0.23 (Figure 3.5B)
indicating that we were not able to observe intermolecular FRET at 1.5 µM Tau making
it unlikely that intermolecular FRET is occurring at lower concentrations.
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3RS-Tau’s N- and C- termini interact in the static state on paclitaxel and GMPCPP
stabilized microtubules but this interaction is reduced in the diffusive state. Having
completed our control experiments, we imaged the behavior of dual labeled (Alexa
488/647) N&C 3RS-Tau on Alexa 405 labeled, paclitaxel stabilized microtubules. Within
the dual labeled preparation, only ~20 % of the Tau molecules were labeled with both the
donor and the acceptor. In order to identify dual labeled events for further analysis, we
imaged using TIRF microscopy with ALEX.
In addition to separating N&C 3RS-Tau behavior into static and diffusive
binding events as described in the methods, dual labeled tracks were used to calculate the
frame by frame intensity values (

,

,

) needed to determine average S and E for

static and diffusive binding events.
As we have previously shown, 3RS-Tau favors static binding on paclitaxel
stabilized microtubules (McVicker et al., 2014; Stern et al., 2017). To increase our
chances to observe diffusive behavior, we imaged N&C 3RS-Tau on GMPCPP
microtubules (Figure 3.6) where it has been shown that 3RS-Tau’s binding equilibrium is
shifted towards the diffusive state (McVicker et al., 2014). We found that for both lattice
structures, the N- and C-termini interact closely in the static state (Figure 3.6&3.7) while
this interaction is reduced in the diffusive state (Figure 3.6&3.7).
3.5 Discussion
Over the last three decades cryo-EM, NMR and single molecule imaging have
begun to elucidate Tau structure and function on the microtubule surface (Hirokawa et
al., 1988; Al-Bassam et al., 2002; Santarella et al., 2004; Jeganathan et al., 2006;
Elbaum-Garfinkle and Rhoades, 2012; Kadavath et al., 2015). Cryo-EM studies hint at
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the dynamic nature of Tau binding (Al-Bassam et al., 2002). However, the staticdiffusive state binding equilibrium was not observed until recent TIRF studies were
performed (Hinrichs et al., 2012). If distinct structural changes occur on the microtubule
surface, they could not be observed with NMR, cyro-EM and solution based FRET
(Hirokawa et al., 1988; Al-Bassam et al., 2002; Santarella et al., 2004; Jeganathan et al.,
2006; Elbaum-Garfinkle and Rhoades, 2012; Kadavath et al., 2015). In the case of NMR
and cryo-EM, averages of the microtubule associated portion of the protein were
observed but no structure could be observed away from the microtubule surface (AlBassam et al., 2002; Santarella et al., 2004; Kadavath et al., 2015). Solution based FRET
experiments revealed a folded conformation for Tau (Jeganathan et al., 2006; ElbaumGarfinkle and Rhoades, 2012) but these assays could not be used to image structural
differences between static and diffusive binding on the microtubule surface. Though
these studies did not focus on the structural changes that underlie static versus diffusive
binding, along with our own observations of Tau N-terminal phosphorylation mediated
modulation of kinesin-1 motility (Stern et al., 2017), they led us to hypothesize that Tau
binds the microtubule surface in multiple conformations which are regulated by Tau Nand C-termini interactions and that global conformational change underlies static and
diffusive microtubule binding. In order to observe potential structural changes on the
microtubule surface, we developed a three color smFRET TIRF assay using ALEX to
image Alexa 488/647 labeled Tau on Alexa 405 labeled microtubules.
Based on our hypothesis, any conformational change would be most noticeable
in the interaction between the N- and C-termini. Therefore we chose N&C 3RS-Tau as a
first test of our system. Our experimental procedure allows us to correlate behavioral
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changes with changes in energy transfer efficiency for static and diffusive events. Our
DNA oligomer controls demonstrate that we are able to measure energy transfer
efficiencies between 24 Å and 71 Å (Figure 3.3&3.4). Our results report the average
interactions of N&C 3RS-Tau in the static and diffusive state (Figure 3.6&3.7) however,
other structural changes exist may occur.
Our smFRET experiments show that the N- and C-termini interact closely in the
static state on both paclitaxel and GMPCPP stabilized microtubules while the interaction
is reduced in the diffusive state (Figure 3.8). This interaction suggests that Tau binds the
microtubule surface in a folded conformation which is more compact in the static state.
The more open confirmation that underlies diffusive binding may be the result of Tau
interactions with tubulin C-terminal tails (CTT). It has previously been shown that
diffusive behavior is dependent on CTT (Hinrichs et al., 2012). On subtilisin treated
microtubules the frequency of binding is reduced and those events that do occur are
predominantly static (Hinrichs et al., 2012). This supports work demonstrating that the
Tau-microtubule interaction is partially dependent on the CTT and requires interactions
between the CTT and C-terminal residues of Tau (Al-Bassam et al., 2002; Hinrichs et al.,
2012; Di Maïo et al., 2014). Static binding is then the result of the folded conformation’s
inability to interact with the CTT due to shielding of the C-terminal region.
Previous work by our group demonstrates that static Tau is more inhibitory to
kinesin-1 motility than diffusive Tau (McVicker et al., 2011; Stern et al., 2017). A folded
conformation preventing Tau C-terminal interactions with the CTT would allow for more
stable lattice interactions promoting static binding. This would in turn allow Tau to
modulate kinesin-1 run-length. The phosphorylation mediated shift towards diffusive
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binding would result from disruption of N- and C-termini interactions leading to an
equilibrium shift. In addition to regulating kinesin-1 motility, Tau participates in
signaling cascades governing cargo delivery (Morfini et al., 2002; LaPointe et al., 2009;
Kanaan et al., 2012). Phosphorylation of Y18 which facilitates a diffusive state shift, has
also been shown to prevent Tau from participating in signaling cascades (Morfini et al.,
2002; LaPointe et al., 2009; Kanaan et al., 2012). Therefore, the more stable lattice
interactions found in the static state could facilitate Tau involvement in signaling.
However, the more open conformation of the diffusive state would be more accessible for
signaling though this would be phosphorylation dependent. Based on this reasoning Tau
participation in signaling cascades could occur in either the static or diffusive state but,
protein-protein interactions might further alter Tau conformation on the microtubule
surface. Hirokawa et al. (1988) observed an open, extended N-terminal in cryo-EM
micrographs of densely packed Tau-microtubule pellets. It has been shown that Tau
bundles microtubules potentially through N-terminal/N-terminal interactions (Chen et al.,
1992; Rosenberg et al., 2008; Choi et al., 2017). This would lead to the extended Nterminal projections observed by Hirokawa et al. (1988). We do not know how Tau-Tau
interactions or other binding partners would further affect Tau on the microtubule
surface.
Further work must be done with other smFRET constructs to determine the
overall structure of Tau on both paclitaxel and GMPCPP stabilized microtubules.
Additionally, Tau is a heavily post translationally modified protein (Martin et al., 2011).
As we have previously demonstrated, phosphorylation plays a role in regulating Tau’s
behavior and function on the microtubule surface (Stern et al., 2017). It is not hard to see
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how disease state modifications to Tau would affect its bound structure and therefore its
function beginning at early disease development time points. Future work with Tau will
allow us to understand how disease and non-disease state phosphorylation events (such as
Y18 phosphorylation) may affect Tau’s bound structure and whether the structural
changes we have observed in vitro occur in vivo under normal and disease state
conditions. This work highlights the need for continued study of factors which regulate
Tau’s static-diffusive microtubule binding equilibrium.
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Figures

Figure 3.1: Tau constructs and imaging setup.
A) To create the 3RS-Tau constructs used in these experiments, site directed
mutagenesis was used to change the naturally occurring cysteine to an isoleucine
(C322I), which is the residue that occurs in other binding repeats at this position.
Residues in the N- and C- termini (T17 and S346) were mutated to cysteines to create
N&C 3RS-Tau. B) An inverted Eclipse Ti Microscope with two iXON Ultra EMCCD
cameras was used to perform TIRF microscopy with ALEX. Labeled Tau was imaged
by alternating exposure with 640 nm and 488 nm argon lasers. Alexa 405 labeled
microtubules were imaged with a 405 nm laser.
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Figure 3.2: Comparison of Singly labeled N 3RS-Tau and C 3RS-Tau to WT
3RS-Tau.
To control for the effect of labeling 3RS-Tau at the N- or C-termini with either Alexa
488 or 647, single cysteine constructs (N 3RS-Tau and C 3RS-Tau) were labeled with
either Alexa 488 or 647. TIRF microscopy was used to perform behavioral assays
comparing Alexa 488 or 647 singly labeled WT, N and C 3RS-Tau. A) Kymographs
of N 3RS-Tau and C 3RS-Tau labeled with either Alexa 488 or 647. All constructs
demonstrated static (straight lines) and diffusive (jagged lines) binding. B) Histogram
of percent static binding for WT, N and C 3RS-Tau labeled with Alexa 488 and 647.
No significant difference was observed for either label or labeling position (p > 0.05).
See Supplemental Table S2.1.
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Figure 3.3: Kymographs for DNA oligomer smFRET controls of High,
Intermediate and Low FRET.
The High FRET oligomer was designed by labeling the 5’ and 3’ end of a two turn
oligomer with Alexa 488/647. The Intermediate FRET oligomer was designed by
labeling both 5’ ends of a one and a half turn oligomer with Alexa 488/647. To create
the Low FRET oligomer, the same sequence used for the High FRET oligomer was
dual labeled at the 5’ ends with Alexa 488/647. Donor (

) and acceptor (

) labeled

events were tracked and intensities were measured in donor, acceptor and energy
transfer (

) channels. These intensities were background corrected and photo-

bleaching events were used to calculate constants for donor bleed through into the
acceptor channel (χ) and the difference in the system’s sensitivity to detect donor vs.
acceptor fluorophores (γ). These constants were then used to calculate both FRET
efficiency and labeling stoichiometry.
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Figure 3.4: Stoichiometry (S) versus Average Efficiency (E) plots for DNA
oligomer smFRET controls for High, Intermediate (Inter) and Low FRET states.
Dual labeled DNA oligomers of varying length and fluor position were used to test
the imaging system’s ability to detect changes in FRET efficiency based on the R0
(arrow; 52.7Å) for Alexa488/647. We found that we were able to detect efficiency
changes within the Low to High FRET range of 24 Å to 71 Å. Importantly, we were
also able to distinguish intermediate FRET efficiencies from high FRET efficiencies
(Intermediate: 0.52 ± 0.11). Furthermore, the average FRET efficiency for the
Intermediate oligomer agrees with our calculated R0 (52.7 Å).
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Figure 3.5: Intermolecular FRET was not observed under our smFRET imaging
conditions.
A) To ensure that our smFRET events represent only dual labeled single molecule
binding events and not intermolecular interactions between interacting molecules, we
imaged singly labeled Alexa 488 and 647 WT, N and C 3RS-Tau both at 20X the
concentration (1 nM). Kymographs above are representative of overlapping Alexa
488 (

) and 647 (

). No signal was observed in the energy transfer channel (

).

B) Average S and E plot for Alexa 488 and 647 singly labeled static and diffusive
events that overlap tracked in the donor channel (average S = 0.90 ± 0.10; average E
= 0.04 ± 0.09; N = 9) and measured with MTrackJ in all channels. No significant
difference was observed compared to the Low DNA oligomer (P > 0.05; T-test with
Welch’s correction).
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Figure 3.6: Kymographs of dual labeled N&C 3RS-Tau.
Static and diffusive events were tracked and measured in the donor, acceptor
and energy transfer channels (

,

,

). Signal was observed in the

channel for static events on both paclitaxel and GMPCPP stabilized
microtubules. No signal was observed in this channel for diffusive events on
either lattice.
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Figure 3.7: Average S and E plots for static and diffusive.
There was a significant difference (P < 0.05, T-test with Welch’s correction)
between static events (E = 0.57 ± 0.21; S = 0.45 ± 0.12; N= 6) and diffusive
events (E = 0.07 ± 0.26; S = 0.49 ± 0.10; N= 6) on both lattice structures.
The N- and C-termini of 3RS-Tau interacts more closely in the static state
than the diffusive state. This indicates that Tau is more folded on the static
state than the diffusive state on both paclitaxel and GMPCPP.
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Figure 3.8: Model of N- and C-termini interactions while Tau (red and gray) is
bound to the microtubule (green) in both the static and diffusive state.
Our results show that the N- and C-termini interact closely in the static state while the
interaction is reduced in the diffusive state. Reduced interaction the diffusive state
may allow for increased interaction between Tau’s C-terminal residues and tubulin’s
C-terminal tail (CTT). This interaction has previously been shown to facilitate
diffusive binding (Hinrichs et al. 2012). In the static state, increased N- and C-termini
interaction may in turn reduce Tau-CTT interactions. These results represent the first
in vitro single-molecule structural study of dynamic Tau binding on the microtubule
surface.
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Supplemental Table S3.1: Behavioral Data for Singly Labeled 3RS-Tau
Control Constructs

Table showing behavioral data for WT, N and C 3RS-Tau labeled Alexa 488 or 647.
All data was collected on Alexa 405 labeled paclitaxel stabilized microtubules. No
significant difference was found in behavior for any construct with either label
(Fisher’s Exact Test; p > 0.05). Data was analyzed using a sliding window analysis to
determine static or diffusive behavior. No differences were seen in static or diffusive
dwell times and alpha values calculated for diffusive events from each construct and
labeling condition did not differ greatly. Label type and position does not affect 3RSTau binding behavior.
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Figure S3.1: Biotinylated DNA oligomers dual labeled with Alexa 488/647.
Labels placed at fixed distances were used to control for high, intermediate and low
FRET conditions based on the calculated R0. Upon acceptor photo-bleaching, these
oligomers were also used to calculate the constants χ (donor bleed through in the
acceptor channel) and γ (sensitivity differences when detecting donor vs. acceptor
fluorophores) needed to calculate E and S:

and

132

CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
Tau performs many functions within axonal transport, which must be carefully
regulated to ensure neuronal health. This work explores the link between regulation of
Tau behavior and function while examining the structural changes that underlie this
regulation. In chapter two we demonstrate that phosphorylation regulates Tau function on
the microtubule surface, while in chapter three we provide the first evidence for structural
change underlying static versus diffusive binding.
Work with tyrosine 18 (Y18) up to this point has focused on its participation in
signaling cascades (LaPointe et al., 2009; Kanaan et al., 2012) and its potential role in
stabilizing a dynamic folded conformation of Tau in solution (Jeganathan et al., 2006).
However, Y18 involvement in the regulation of Tau behavior and function on the
microtubule surface has not been previously demonstrated. It has just recently been
shown that Tau is able to bind the microtubule in a static-diffusive state equilibrium
(Hinrichs et al., 2012; McVicker et al., 2014) and the purpose of this equilibrium has just
begun to be understood (McVicker et al., 2011; Stern et al., 2017). While we work to
understand Tau’s dynamic bound equilibrium, other questions remain to be answered.
Within the field, the study of Tau post-translational modifications (PTMs) mostly
relates to Tau phosphorylation and the studied phosphorylation is usually disease state
associated (Martin et al., 2013b). While our work with Y18 phosphorylation in chapter
two represents the first evidence that non-disease state regulation of Tau modification can
affect its behavior and function, it also serves to highlight a significant gap in our
knowledge. As a field we have not focused on non-disease state Tau regulation by
phosphorylation or other PTMs. Additionally, though we have demonstrated that Tau can
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bind both statically and diffusively ex vivo, no work has not been done to address the
cellular relevance of this behavior to motor motility modulation.
Experiments building on the work presented in chapter two should explore the
relevance of Tau’s static-diffusive state equilibrium on the movement of kinesin-1 within
the cell. While we have shown that the Y18 phosphorylation mediated shift towards
diffusive binding is maintained ex vivo, we have not examined ex vivo or in vivo motor
motility in the presence of Tau. In vivo work could be done by co-expressing GFP labeled
kinesin-1 with either WT or Y18E 3RS-Tau in a neuronal cell line such as CAD, which
does not express Tau (Bisig et al., 2009). Given the increase in ionic strength and
crowding, it is important to establish that the in vitro effect we observed is maintained
within the cell.
In addition to cargo binding and motor motility, Y18 has been implicated in the
stabilization of a solution based dynamic folded conformation of Tau (Jeganathan et al.,
2006). The possible involvement of Y18 in the regulation of Tau structure led us to the
question the role of structural change in Tau behavior and function on the microtubule
surface. Phosphorylation of Tau microtubule binding regions has been shown to reduce
its affinity for the microtubule surface. However, in chapter two we show that Y18
phospho-mimetics also exhibit reduced affinity for the microtubule surface. Y18 is found
in Tau’s projection domain, which does not bind the microtubule (Goode et al., 2000).
This raises the question of how Y18 phosphorylation in the N-terminal region affects the
affinity of the protein for the microtubule. One possible explanation for this Y18
mediated drop in affinity is that Y18 phosphorylation affects long range structural
changes while Tau is bound to the microtubule.
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Though Tau structure has been studied both on and off the microtubule, no work
has been done to understand how Tau’s structure may change with static and diffusive
binding. Cyro-EM creates snap shots of static binding and cannot be used to study Tau’s
dynamic binding behavior and the structural changes that may occur. Solution based bulk
and single molecule FRET studies have been used to study Tau microtubule interactions,
but like cryo-EM are not currently used to study dynamic behavioral changes on the
microtubule surface. To address this gap in knowledge, we have used smFRET
techniques detailed in chapter three to observe differences in Tau N- and C-termini
interactions.
Our work on Tau’s microtubule bound structure encompasses the development of
the reagents, imaging and analysis methods needed to test the hypothesis that Tau binds
the microtubule in distinct conformations which underlie static and diffusive binding. We
have demonstrated the efficacy of our system using N&C 3RS-Tau to show that there is a
difference in the average N- and C-termini interactions between the static and diffusive
state. However, we have not completed testing other labeling positions within the protein
(Figure 4.1). Preliminary work with N&3 3RS-Tau suggests that there is little to no
interaction between the N-terminal and the 3rd microtubule binding repeat in both the
static and diffusive state (Alisa Cario, personal communication). We have yet to test the
interactions between the C-terminal and the 3rd microtubule binding repeat. The results
from these three labeling positions (N&C 3RS-Tau, N&3 3RS-Tau and 3&C 3RS-Tau)
based on previously published solution based FRET assays (Jeganathan et al., 2006)
should give us an overall structure for Tau bound in both the static and diffusive state
(Figure 4.1). To validate our work or in the case that the chosen labeling sites are not
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sufficient, other positions previously used for dual labeling such as sites in the 1st and 2nd
microtubule binding repeats, acidic inserts and proline rich region can be used
(Jeganathan et al., 2006; Elbaum-Garfinkle and Rhoades, 2012).
In chapter three we report the average stoichiometry and efficiency of energy
transfer for static and diffusive behavior based on averages for individual events.
Therefore, we report average differences when Tau is bound in the static versus diffusive
state. Since the focus of this work is on average conformational change during static and
diffusive binding, it is highly likely that additional structural transitions occur that we
have not observed. Further analysis of our data would allow us to determine how
dynamic the interactions in the static and diffusive state are. Probability distribution
analysis can be used to predict the shape of smFRET histograms for molecules
interconverting between states (Santoso et al., 2010). Fitting the expected probability
distributions for different states to histograms of our frame-to-frame E data would allow
us to determine if Tau has dynamic transitions in the static and diffusive state. Similarly,
Hidden Markov Modeling can be used to detect transition states that have been obscured
by the noise in a system (McKinney et al., 2006). Using this approach a transition
probability matrix and emission probability functions could be used to fit our
experimental data and determine the points at which transitions were likely (McKinney et
al., 2006). Fluorescence cross-correlation spectroscopy (FCS) in combination with TIRFbased single-molecule FRET could be used to obtain information about the time-scale of
dynamics for specific structural transitions in Tau in the presence of microtubules.
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Figure 4.1: Tau’s Overall Bound Structure
Work in chapter three shows that Tau’s N- and C-termini on average, interact more
closely in the static than the diffusive state (solid double-headed arrow). However,
work must be done to understand the interactions between the N-terminal and the
microtubule binding repeats (dashed double-headed arrow), and the C-terminal and the
microtubule binding repeats (dashed double headed arrow). Dual labeled N&3 and
3&C 3RS-Tau constructs have been made and work has begun with N&3 3RS-Tau.
Other labeling sites can be chosen in the 1st and 2nd microtubule binding repeats, acidic
inserts and proline rich region to further define and validate Tau’s microtubule bound
structure.
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Ultimately our work with single molecule fluorescence resonance energy
transfer (smFRET) will allow us to correlate behavioral changes with FRET efficiency
changes on the microtubule surface. As we have demonstrated, we have the means to
perform frame-to-frame background correction and calculate average FRET efficiency
and average stoichiometry of labeling. However, the methods used to determine static
versus diffusive binding identify whole events as static or diffusive and do not allow us to
identify state transitions that may occur during an event. The next step is implementing
MATLAB code for a sliding window analysis to identify these transitions and calculate
mean squared displacement and α values for diffusive events. We are currently working
to complete this next phase of analysis which will allow us to better define the static and
diffusive states and better correlate FRET efficiency changes with changes in behavior.
Over the years, cryo-EM studies of microtubule bound Tau have attempted to
solve Tau structure on the microtubule surface. Together, these studies show that Tau
binds the microtubule along protofilaments potentially close to α-tubulin (Hirokawa et
al., 1988; Al-Bassam et al., 2002; Santarella et al., 2004). The most recent cryo-EM
study has been able to resolve microtubule binding repeats to a much higher resolution
than any other (Kellogg et al., 2018). This study shows that Tau microtubule binding
repeats bind in tandem along tubulin dimers (Figure 4.2) (Kellogg et al., 2018). Each
binding repeat was found to be fully extended across three tubulin monomers (Figure 4.2)
(Kellogg et al., 2018). These results indicate that while on the microtubule surface, the
microtubule binding repeats are extended but, as with the other cryo-EM studies, the
regions of Tau that extended away from the microtubule were not resolved.
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In conjunction with our work in chapter three, these results lead to the hypothesis
that Tau’s N- and C-termini interactions in the static state facilitate microtubule binding
repeat extension while bound to the microtubule surface. Unfortunately, the recent cryoEM work (Kellogg et al., 2018) did not resolve portions of Tau that extend away from the
microtubule surface and cannot be used to observe dynamic structural change. However,
this work highlights new fluor placement positions for use in our smFRET assay. Our
current dual labeling sites do not take into account changes in the interactions of the
microtubule binding repeats. While a distance of 80 Å between repeats (Figure 4.2) is
outside the R0 measured for Alexa 488/647, placement of probes at the end of one repeat
and the center of another repeat should allow us to observe any changes that may occur to
the extension of the repeats in the static and diffusive state. If we could replicate the
results of the cryo-EM work where the microtubule binding repeats are fully extended
and therefore should be in a low FRET state, we would not only validate our system but
demonstrate that it can be used to compliment cryo-EM data. Using both approaches
would allow us to make significant progress in our understanding of Tau’s dynamic
structure on the microtubule structure.
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Figure 4.2: smFRET experiment to determine how microtubule binding repeats
interact in the static and diffusive state.
New cryo-EM work shows that Tau microtubule binding repeats (red rectangles)
interact with the microtubule (green) in tandem. While the dual labeled constructs we
plan to use for ongoing smFRET assays do not cover interactions between microtubule
binding repeats, this study highlights the need to include dual label sites within the
binding repeats. Each repeat stretches 80 Å (Kellogg et al., 2018), a distance which is
outside the range of the Alexa488/647 FRET pair. However, placement of
fluorophores (yellow/red oval) at the end of one repeat and the middle of another
(~40-50 Å distance) would allow for observation of structural changes with static or
diffusive binding and allow us to validate our smFRET assay.

140

Figure 4.3: Effect of phosphorylation on Tau’s microtubule bound structure.
In chapter two we demonstrate that phosphorylation at Y18 affects Tau behavior and
function on the microtubule surface. Our work in chapter three shows that Tau’s Nand C-termini interact more closely in the static than the diffusive state. Given that
phospho-mimetics of Y18 shift Tau’s binding equilibrium towards the diffusive state,
we hypothesize that Y18 phosphorylation may disrupt N-C termini interactions
thereby shifting the structural equilibrium to a more open conformation and the
behavioral equilibrium towards diffusive binding. Currently, no work has been done to
determine how phosphorylation affects Tau structure on the microtubule surface.
Therefore to test this hypothesis we have generated Y18E 3RS-Tau smFRET
constructs for all three positions (N&C, N&3, 3&C) for use in smFRET assays.
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In chapter two, we demonstrate that phosphorylation regulates behavioral and
functional change. However, it is not known how non-disease state phosphorylation
events affect Tau’s bound structure. In light of our work in chapter’s two and three, we
can hypothesize that Y18 phosphorylation disrupts N-C termini interactions thereby
shifting the structural equilibrium to a more open conformation and the behavioral
equilibrium towards diffusive binding. To test this hypothesis, we have generated Y18E
3RS-Tau smFRET constructs for all three positions (N&C, N&3, 3&C) for use in
smFRET assays (Figure 4.3).
In addition to understanding how post-translational modifications affect Tau
structure, we are also able to ask questions about other aspects of the Tau-microtubule
interaction including patch formation, interactions with the microtubule in the static and
diffusive state, and the physiological relevance of Tau structure. It has been shown that
Tau binds the microtubule cooperatively and forms patches in the static state at high
concentrations (Dixit et al., 2008; McVicker et al., 2014). However, the structural
changes that underlie these patches and the Tau-Tau interactions that may occur are not
well understood. It is hypothesized that N-termini intermolecular interactions, possibly
through the acidic inserts, allow patch formation since 4RL-Tau (two acidic inserts)
appears to form larger patches than 3RS-Tau (no acidic inserts) (Dixit et al., 2008). To
determine the structure of Tau within these patches, smFRET total internal reflection
fluorescence (TIRF) microscopy experiments with alternating laser excitation (ALEX)
could be performed on unlabeled microtubules with high concentrations of Alexa 405
labeled WT Tau (20-50 nM) spiked with a much lower concentration (500 pM) of Alexa
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488/647 dual labeled Tau. This would allow for patch identification (Alexa 405) and
imaging of Tau structure (Alexa488/647) within these patches.
The future integration of TIRF with fluorescence correlative spectroscopy (FCS)
would allow us to identify potential Tau-Tau interactions within patches. Single donor
and acceptor N-terminal labeled populations of WT Tau could be spiked into the same
experimental setup described above. This technique would allow the resolution of Tau
molecules within a patch and with the smFRET data would help us understand patch
formation and composition and how that relates to observed Tau interactions within
patches.
As explained in chapter three, tubulin C-terminal tails (CTT) have been shown to
regulate Tau diffusive binding. In their absence, Tau has been shown to bind statically to
the microtubule surface (Figure 4.4) (Hinrichs et al., 2012). To further demonstrate the
differences that underlie static versus diffusive binding and elucidate the involvement of
the CTT in this process, smFRET assays can be performed on microtubules with and
without CTT (Figure 4.4) (-/+ subtilisin treatment (Hinrichs et al., 2012)). In addition to
Tau structural changes with and without CTT, experiments can be performed to better
understand the interactions that occur between Tau and the CTT. To carry out this
experiment, the CTT would be acceptor labeled while Tau would be singly labeled with a
donor probe (perhaps starting with the C-terminal since its truncation has been shown to
reduce diffusive binding). Tubulin CTT could be tagged for labeling using a number of
methods the most attractive being tubulin tyrosine ligase attachment of an unnatural
amino acid (3-formyltyrosine) to the α-tubulin CTT and subsequent labeling with Alexa
647 hydrazide (Banerjee et al., 2010). This would allow labeling of our existing bovine
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brain tubulin stock with fluorophore without the need to express tubulin fused with a
bulky protein tag or fluorescent marker. smFRET experiments could be performed using
TIRF and ALEX. Though the preparation for these experiments would be challenging,
they would allow us to better understand the interactions that dictate diffusive behavior.
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Figure 4.4: Tubulin C-terminal tails (CTT) allow Tau to bind diffusively.
Tubulin CTT have been shown to facilitate Tau diffusive binding on the microtubule
surface. Treatment to remove CTTs leads to the loss of diffusive behavior as seen in
the kymographs (Hinrichs et al., 2012). Our results for N&C 3RS-Tau show that the
N- and C-termini are farther apart in the diffusive state than the static state. This
change in interaction may be due to Tau C-terminal interactions with tubulin CTT.
The Tau C-terminal has been shown to interact with the CTT and truncation of the Tau
C-terminal leads to loss of diffusive binding (Hinrichs et al., 2012). smFRET assays of
dual labeled Tau with and without the CTT would allow us to observe how the
presence of the CTT affects Tau structure. Additionally, smFRET could also be
performed between the Tau C-terminal and the CTT to increase our understanding of
the interactions that take place between Tau and tubulin. Figure (kymographs) adapted
from Hinrichs et al., (2012) in accordance with the Creative Commons Attribution
license.
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Our ultimate goal is to adapt this smFRET assay for the identification of small
molecules or other agents that may be efficacious in stabilizing non-disease state
conformations under disease state conditions. One of the first steps to determining the
feasibility of this idea is to establish that the structural changes we observed in vitro
occur under physiological conditions. Increasing salt concentration and adding crowding
agents to our existing smFRET assays would allow us to mimic some but not all of the
conditions present in the cell. Carrying out smFRET experiments in squid axoplasm
could be a means to recreate physiological conditions before moving to more challenging
systems such as mammalian neuronal cell types. Squid axoplasm could be prepared as
detailed in chapter two. Alexa 405 labeled Tau would be used to coat the axoplasmic
microtubules and low concentrations of dual labeled Tau would be spiked in to observe
structural changes of Tau on axoplasmic microtubules.
After confirming that the changes we observe in vitro occur under physiological
conditions, we can test our smFRET assay’s ability to detect structural changes in the
presence of single molecules. Heparin is known to induce a disease state conformation of
Tau and has been used to study Tau conformational change in solution (ElbaumGarfinkle and Rhoades, 2012). We could image dual labeled Tau interacting with Alexa
405 microtubules in the presence and absence of heparin. This experiment would
demonstrate our ability to observe structural changes caused an already studied small
molecule and open the way for us to test other small molecules which may affect Tau
structure. Comparing Tau structure with and without heparin would also allow us to
determine which dual labeling position would be best for use in a high throughput screen.
Ideally, interactions at these positions should only change in the presence of heparin.
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Using these positions, we could simplify and automate our assay to test small molecule
libraries for promising targets that restore wildtype interactions to populations of disease
state Tau. Ultimately, these targets could have use in the treatment of Alzheimers disease
and other Tauopathies.
Though the future experiments discussed above are challenging in their
execution, they represent ways in which we can build on the work presented here to
further our understanding of the role of Tau in axonal transport and the means by which it
regulates motor motility and cargo delivery. The smFRET assay especially, lays the
groundwork for an entirely new direction of thought and will allow us to answer
questions, which were previously beyond reach.
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